THE MEDICAL CLINICS OF NORTH AMERICA

Med Clin N Am 86 (2002) 1553–1599

Cumulative Index 2002

Volume 86

January	COMPLEMENTARY AND ALTERNATIVE MEDICINE, pages 1–204
March	TICK-BORNE DISEASES, pages 205–454
May	DEMENTIA, pages 455–686
July	HOSPITAL MEDICINE: ORGANIZATION, QUALITY IMPROVEMENT, AND CLINICAL CARE, pages 987–924
September	ASTHMA, pages 925–1164
November	RECENT ADVANCES IN GASTROENTEROLOGY, pages 1165–1599

Note: Page numbers of article titles are in **boldface** type.

A

Abacavir, for AIDS dementia, 545–546

Abdominal pain
- esophagogastroduodenoscopy for, 1175
- in irritable bowel syndrome, 1527, 1545

Abetalipoproteinemia, small intestinal manifestations of, esophagogastroduodenoscopy in, 1197–1198

Abuse, irritable bowel syndrome in, 647–648

Acetaminophen, for pain, 786

Achalasia
- botulinum toxin injection for, endoscopic ultrasonography with, 1307
- esophagogastroduodenoscopy in, 1176, 1194

Acidosis, in asthma, treatment of, 1060

Acquired immunodeficiency syndrome. *See* AIDS dementia; Human immunodeficiency virus infection.

Acrodermatitis chronica atrophicans, in Lyme disease, 265

Activated protein C, for sepsis, 805–807

Activating peptide-1, in corticosteroid-resistant asthma, 1083

Activities of daily living
- deterioration of, in hospital, 712–713
- evaluation of, in dementia, 457–458

Acupressure, 113

Acupuncture, 70–72, 113, 176

Acute care for the elderly (ACE) units, in outcomes evaluation, 725–726

AD. *See* Alzheimer's disease.

Addiction, to opioids, 790–791

Adenoma(s), gastric, esophagogastroduodenoscopy in, 1198–1199

S-Adenosyl-L-methionine, as dietary supplement, 138

Adhesion molecules, inhibitors of
- for asthma, 1142
- for inflammatory bowel disease, 1511

Adhesions, small intestinal, laparoscopic surgery on, 1414

Admission, communication in, 900

Adrenergic receptors, function of, 991–992

Advance directives, 753

Adverse events, in hospital care
- epidemiology of, 850–853
- incident reporting of, 858–861
- versus errors, 851, 853

Aging, cognitive function changes with, 461–462

0025-7125(02)/$ - see front matter © 2002, Elsevier Science (USA). All rights reserved.
PII: S0025-7125(02)00137-2

Agitation, in dementia, treatment of, 645–646

Agni, in Ayurvedic medicine, 76, 78–79

AIDS dementia, **537–550**
clinical features of, 539
diagnosis of, 542–543
disease characteristics and, 538–539
epidemiology of, 540
monitoring of, 542–543
pathology of, 540–542
treatment of, 543–547

Airway
inflammation of, leukotrienes and leukotriene modifier effects on, 1010, 1013
remodeling of, in asthma, 930–931
leukotriene modifier effects on, 1013–1014

Albuterol, for asthma, 997, 1000–1001, 1056, 1062

Alcoholism, transcendental meditation for, 14

Alkali ingestion,
esophagogastroduodenoscopy in, 1175

Allergic rhinitis, asthma with, 1103

Allergy
definition of, 937
homeopathy for, 54, 56–57
immunotherapy effects on, in asthma, 1092–1094

Allium, in homeopathy, 54

Allopathy
versus Chinese medicine, 65–66, 68
versus homeopathy, 49

Alosetron, for irritable bowel syndrome, 1540–1541

Alpha-synuclein, mutations of, in dementia with Lewy bodies, 521, 530

Alternaria allergens, environmental controls for, 984–986

Alternative medicine. *See* Complementary and alternative medicine.

Alzheimer's disease
amyloid precursor protein in, 593–594, 629–630
apolipoprotein E in, 583, 596, 632
beta-amyloid in, **629–638**
beta-secretase in, 630, 634–637
clinical features of, 456–460, 591, 655
diagnosis of, 465–466
clinical evaluation in, 456–460
for epidemiologic studies, 573–574
differential diagnosis of, 577–578
diffuse Lewy bodies in, 521–522
economic impact of, 455
epidemiology of, 480–481, 573, 578–580, 592, 655
familial, 592–593
genetics of, 582–583, 593–597, 615–627, 630–637
late-onset, 597
London mutations in, 631–634
pathogenesis of, 632–633, 657
pathology of, 591–592, 629, 635–636
presenilins genes in, 594–596, 632, 634–635
prevention of, 582
risk factors for, 580–582, 592, 630–632
Swedish mutations in, 631, 634
Tau protein defects in, **615–627**
transgenic models for, 635–636
treatment of, 655–666
cholinesterase inhibitors in, 657–664
disability minimizing in, 656
ginkgo biloba in, 665–666
nonpharmacologic, 656
severe, 663–664
vitamin E in, 664–665
versus vascular dementia, 480–481, 488–489

Ama hypothesis, in Ayurvedic medicine, 79

Amblyomma americanum (Lone Star tick)
attachment sites of, 223
in disease transmission
ehrlichiosis, 377, 381
tick paralysis, 441
morphology of, 244

Amebiasis, colonoscopy in, 1257

American Neurologic Society, neurologic Lyme disease guidelines of, 267–268

5-Aminolevulinic acid, in photodynamic therapy, for Barrett's esophagus, 1437

Aminophylline, for asthma, 1062–1063

Aminosalicylates, for inflammatory bowel disease, 1500–1501

Amitriptyline, for pain, 789

Amnestic syndromes, versus dementia, 464

Amoxicillin, for Lyme disease, 270
chronic, 345–346
for *Helicobacter pylori* infection, 1459–1460
in arthritis, 305
in carditis, 292

in erythema migrans, 255

Amprenavir, for AIDS dementia, 545

Amyloid angiopathy, dementia in, 486

Amyloid precursor protein, defects of, in Alzheimer's disease, 593–594, 629–637

Amyloidosis, in Alzheimer's disease, 591–592. *See also* Beta-amyloid.

Anal fissures, sigmoidoscopy in, 1254

Anaplasmosis. *See* Ehrlichiosis.

Anastomosis, in gastrointestinal surgery, ulcers of, 1191

Anemia
iron deficiency, colonoscopy in, 1225–1226
pernicious, atrophic gastritis in, esophagogastroduodenoscopy in, 1177

Anesthesia
for asthma, 1064
for colonoscopy, 1236–1237
for esophagogastroduodenoscopy, 1182–1184
for laparoscopic surgery, 1401–1402
hypnosis with, 20–21

Angiodysplasia
colonic
colonoscopy in, 1259–1260
endoscopic diagnosis and therapy of, 1350
interventional radiology in, 1371
esophagogastroduodenoscopy in, 1190–1191

Angiography
in gastrointestinal bleeding
chronic, 1376
colonic, 1225–1226
lower, 1369–1374
small intestinal, 1346
upper, 1359–1365
diagnostic, 1359–1362
therapeutic, 1362–1365
in mesenteric ischemia
chronic, 1387–1388
in arterial disease, 1379–1383
in venous thrombosis, 1384
mesenteric, versus colonoscopy, 1276

Angiopathy, amyloid, dementia in, 486

Angioplasty, in mesenteric ischemia, 1388, 1390

Animal proteins, in asthma
environmental controls for, 979–981
occupational, 958

Ankylosing spondylitis, manipulation techniques for, 95

Anorectal varices, sigmoidoscopy in, 1254

Anorexia nervosa, massage therapy for, 166

Anoscopy, 1218, 1220

Anthroposophic medicine, 54–55

Anti-immunoglobulin E. *See* Omalizumab.

Antibiotics. *See also specific antibiotics.*
for asthma, 1063
for chronic obstructive pulmonary disease exacerbations, 817
for inflammatory bowel disease, 1502–1503
for tick bites, 227–228
prophylactic, for endocarditis
in colonoscopy, 1233–1234
in esophagogastroduodenoscopy, 1170

Antibody(ies)
blocking, in asthma, immunotherapy effects on, 1094–1096
Borrelia burgdorferi. See Lyme disease, laboratory testing for, immune response assays in.
Helicobacter pylori, detection of, 1456–1457
monoclonal, for asthma, 1143. *See also* Omalizumab.

Anticholinergics
for asthma, 1057
for irritable bowel syndrome, 1539

Anticoagulants
for vascular dementia, 489
management of
in colonoscopic polypectomy, 1233
in esophagogastroduodenoscopy, 1170, 1179
perioperative, 743–746

Anticonvulsants, for pain, in end-of-life care, 760

Antidepressants
for irritable bowel syndrome, 1540
for pain, 760, 789
for vascular dementia, 492

Antidiarrheal agents, for irritable bowel syndrome, 1538–1539

Antiemetic agents, in end-of-life care, 762–763

Antiepileptic drugs, for pain, 788–789

Antigen-antibody complexes, *Borrelia burgdorferi*-specific, in Lyme disease testing, 267, 324

Antigen detection assays, for Lyme disease, 319–320

Antihistamines, for asthma, 1023–1024, 1063–1064

Antineutrophil cytoplasmic antibodies, in inflammatory bowel disease, 1498–1500

Antiplatelet agents, for vascular dementia, 491

Antipsychotic agents
for dementia with Lewy bodies, 527–528
for vascular dementia, 492

Antiretroviral agents, for AIDS dementia, 544–546

Antispasmodic agents, for irritable bowel syndrome, 1539–1540

Antitoxin, for tick paralysis, 445

Antitumor agents, injection of, endoscopic sonographic-guided, 1308–1309

Anxiety
eye movement desensitization and reprocessing technique for, 115–116
guided imagery for, 22–23
kava for, 136–137
meditation for, 118–119
mindfulness meditation for, 17–18
relaxation therapy for, 26
transcendental meditation for, 15
valerian for, 134

Aortoenteric fistula
endoscopic diagnosis and treatment of, 1337
esophagogastroduodenoscopy in, 1192

Apathy, in frontotemporal dementia, 505–506

APC gene, mutations of
in colorectal cancer, 1469
in familial adenomatous polyposis, 1480–1481, 1484–1485

Aphasia
in Pick's disease, 502
primary progressive, 507–508
versus dementia, 464

Apolipoprotein E, in Alzheimer's disease, 583, 596, 632

Appendectomy, laparoscopic, 1415–1416

Applied kinesiology, 113–114

Argasidae (soft-bodied ticks). *See also specific tick genera.*
feeding of, 209, 211
life cycles of, 212–213
morphology of, 207–208
taxonomy of, 206

Argon plasma coagulation, for peptic ulcer bleeding, 1324

Argyrophilic inclusions, in Pick's disease, 504

Ariflo phosphodiesterase inhibitor, for asthma, 1140

Arnica, for trauma, 58

Arrhythmias, cardiac, in Lyme disease, 288–290

Arterial disease, mesenteric ischemia in, 1377–1383

Arteriopathy, in CADASIL, 485, 598–599

Arthritis
Ayurvedic medicine for, 84–85
Lyme, **297–309**, 341–342
differential diagnosis of, 301–302
in early disseminated disease, 298–300
fibromyalgia after, 307–308
in late disease
antibiotic-responsive, 300–306
treatment-resistant, 306–307
migratory, 298–300
monarticular, 300–306
pathogenesis of, 274
pathophysiology of, 343
manipulation techniques for, 94–97

Aspergillus allergens, environmental controls for, 984–986

Aspiration, pulmonary, in gastrointestinal bleeding, 1320

Aspirin, for pain, 787

Aspirin-sensitive asthma, leukotriene modifiers for, 1025–1027

Asthma
acute
evaluation of, 1050–1054
treatment of, **1049–1071**
allergic rhinitis with, 1103
aspirin-sensitive, leukotriene modifiers for, 1025–1027

atopy and, 939–940
causes of, occupational, 955–959
classification of, by severity, 1052–1053
compensation for, occupational, 969–970
corticosteroid-resistant, 1079–1084
cytokines in. *See* Cytokines, in asthma.
definition of, 939
occupational, 951–952
refractory, 1073–1074
diagnosis of
acute, 1050–1054
occupational, 959–965
refractory, 1074–1078
severe, 1050–1054
differential diagnosis of
occupational, 965–967
refractory, 1075–1076
disability in, occupational, 969–970
environmental controls for, **973–989**
epidemiology of
occupational, 952–953
refractory, 1078
evaluation of. *See* Asthma, diagnosis of.
exercise-induced
beta-agonists for, 1003
leukotriene modifiers for, 1024–1025
gastroesophageal reflux disease with, 1076–1077
genetics of, **937–950**
history in
acute, 1050–1051
occupational, 961–962
homeopathy for, 56–57
impairment in, occupational, 969–970
in cockroach allergen exposure, 981–983
in fungal exposure, 983–986
in house dust mite allergen exposure, 976–979
in pet allergen exposure, 979–981
in viral infections, 1084
massage therapy for, 169
mild, treatment of, 1018–1022
nocturnal, 1003–1004
occupational. *See* Occupational asthma.
pathogenesis of, **925–936**
airway remodeling in, 930–931
cellular inflammation in, 926
eosinophils in, 927–928
epithelial cells in, 930
fibroblasts in, 930
immunoglobulin E in. *See* Immunoglobulin E, in asthma.
leukotrienes in, 1009–1010
lymphocytes in, 929. *See also* T lymphocytes, in asthma.
macrophages in, 929–930
mast cells in, 926–927, 993, 1098, 1116
neutrophils in, 928–929
occupational, 953–957
pathology of, refractory, 1078–1079
pathophysiology of, 1132–1134
prevention of, occupational, 968
prognosis for, occupational, 968–969
progression of, immunotherapy effects on, 1103
refractory, **1073–1090**
risk factors for, occupational, 957–958
severe. *See also* Refractory asthma.
evaluation of, 1050–1054
treatment of, 1003, 1022–1023, **1049–1071**
severity of, determination of, 1050–1054
treatment of
acute, **1049–1071**
after initial therapy, 1058–1064
anti-immunoglobulin E in, **1113–1129**
antihistamines in, 1023–1024, 1063–1064
antisense oligonucleotides in, 1145–1146
based on inflammation targets, 1134–1142
beta-agonists in. *See* Beta-agonists, for asthma.
chemokine inhibitors in, 1140–1141
corticosteroids in. *See* Corticosteroids, for asthma.
cytokine inhibitors in, 1135–1140
future, **1131–1156**
gene therapy for, 1146–1147
immunotherapy in. *See* Immunotherapy, for asthma.
initial, 1054–1058
leukotriene modifiers in, **1009–1033,** 1040–1041
mechanical ventilation in, 1065–1066
mild, leuketriene modifiers in, 1018–1022
monoclonal antibodies in, 1143. *See also* Omalizumab.
new, 1142–1147
occupational, 967–968
polyethylene glycol moieties in, 1146
refractory, 1084–1087
severe, 1003, 1022–1023, **1049–1071**

Asthma (*continued*)
signaling path modulators in, 1141–1142

Atelectasis, postoperative, 742–743

Atherosclerosis, transcendental meditation for, 14

Atopy
asthma and, 939–940
characteristics of, 938–939
definition of, 937
genetic factors in, 940–945

Atovaquone, for babesiosis, 368–369

Atrial fibrillation, updates on, 817–823
pharmacologic rate control, 819–823
practice guidelines, 818
significance, 818–819

Atrioventricular block, in Lyme disease, 288–290

Atrophic gastritis,
esophagogastroduodenoscopy in, 1177, 1198

Atropine, for death rattle management, 764

Attention disorders, of elderly persons, in hospital, 713–717

Autoimmune disease
massage therapy for, 169
omega-3 fatty acids for, 140

Autonomy, as ethical principle, 871–872, 882

Autopsy, request for, 769

Avoidance, in occupational asthma, 967–968

Ayurvedic medicine, **75–89**
diagnosis in, 79–80
disease concept in, 78–79
for arthritis, 84–85
for obesity, 85
for rheumatism, 84–85
fundamental principles of, 76–78
general concept of, 76–78
medicines for, 81–83
modern relevance of, 85–87
origin of, 75–76
pressure regions in, 78
Rasayana concept in, 77–78, 83–84
reference texts for, 76
therapeutic approach in, 80–81
validation of, 85–87

Azathioprine, for inflammatory bowel disease, 1503–1504, 1512–1513

Azithromycin, for babesiosis, 368–369

B

Babesiosis, **361–373**
clinical manifestations of, 243, 365–367
complications of, 366
diagnosis of, 367–368
epidemiology of, 363–365
historical perspective of, 361
in tick-borne coinfections, 276–278, 364, 367
mortality in, 366–367
pathogen causing, 362–363
prevention of, 369–370
treatment of, 368–369
vectors for, 363–365

Back pain
biofeedback for, 24
chiropractic care for, 99–100
manipulation techniques for, 93–95
osteopathy for, 99

Bacteremia
in colonoscopy, 1275
pneumococcal, treatment of, 803–805

Bacterial colitis, colonoscopy in, 1257

Bactericidal assay, for Lyme disease, 330–331

Banding, of esophageal varices, 1341–1343

Bannwarth's syndrome, 266

Bard endoscopic suturing system, for Barrett's esophagus, 1430

Bariatric surgery, laparoscopic, 1413–1414

Barium studies
in ischemic colitis, 1385
in mesenteric ischemia, 1378
in small intestinal bleeding, 1375
unsatisfactory results from, colonoscopy after, 1226
versus colonoscopy, 1275–1276

Barrett's esophagus, **1424–1445**
chemoprevention in, 1439
diagnosis of, 1424–1426
dysplasia in
importance of, 1433–1435
treatment of, 1435–1438
esophagogastroduodenoscopy in, 1176, 1198
gastroesophageal reflux management in, 1426–1430
guidelines for, 1439
recommendations for, 1440–1441
pathogenesis of, 1423–1426

surveillance of, 1430–1432, 1438

Bartonellosis, in tick-borne coinfections, 277–278

Basophils, in asthma
beta-agonist effects on, 993
immunotherapy effects on, 1098

Beclomethasone, for asthma
inhaled. *See* Corticosteroids, for asthma, inhaled.
leukotriene modifiers with, 1020–1023

Bed rest, in elderly persons, consequences of, 713

Bedding
house dust mite allergen removal from, 976–978
pet allergen removal from, 980

Behavioral disturbances, in dementia, **639–654**
assessment of, 640–642
caregiver information on, 642–649
evaluation of, 457
frontotemporal, 505–506, 602
in Huntington's disease, 599
treatment of, 642–649
vascular, 479
with Lewy bodies, 523–524

Benson method, for relaxation response, 15–16

Benzodiazepines, for esophagogastroduodenoscopy, 1182

Benzyl benzoate, for house dust mite removal, 977–978

Beta-adrenergic receptors
function of, 991–992
pharmacogenetics of, 992–993
structure of, 992

Beta-agonists, for asthma, **991–1008**
acute severe, 1062
beneficial effects of, 993–994
corticosteroids with, 993–994, 999, 1002, 1041–1043
delivery methods for, 996–997
dosages for, 1000–1001
effects of, 993–996
exercise-induced, 1003
in chronic obstructive pulmonary disease, 1004
long-acting, 998–999, 1001–1002
nocturnal, 1003–1004
parenteral, 1062
pharmacology of, 991–993
products for, 997–1001
refractory, 1085
safety of, 995–996
short-acting, 997–1000, 1002, 1055–1057
side effects of, 994
tolerance of, 994–995
versus severity, 1002–1003

Beta-amyloid
in Alzheimer's disease, **629–638**
defects of, 631–636
form 42 in, 632–635
precursor of, 630
in Down's syndrome, 633
normal, 630

Beta-secretase, in Alzheimer's disease, 630, 634–637

Bezoars, gastric,
esophagogastroduodenoscopy in, 1187–1188

Bile ducts, injuries of, in laparoscopic cholecystectomy, 1404–1405

Bill of Rights, Patients', 879

Binswanger's disease, 484–485, 598

Bioenergy, in Chinese medicine, 113

Biofeedback, 23–25

Biopsy
gastric, for *Helicobacter pylori*, 1457–1458
gastrointestinal, endoscopic ultrasonography with, 1303–1304
in colonoscopy, 1238, 1243
in esophagogastroduodenoscopy, 1167
skin, in Lyme disease, 316

Bismuth combination therapy, for *Helicobacter pylori* infection, 1459–1460

Bitolerol, for asthma, 997–998, 1000

Bla g 1 cockroach allergen, environmental controls for, 981–983

Bleeding, gastrointestinal
causes of, 1358–1359, 1365
endoscopic diagnosis and therapy of, 1307, **1319–1356**, 1359
esophagogastroduodenoscopy in, 1171, 1173
in angiodysplasia, 1350
in aortoenteric fistula, 1337
in cancer, 1336–1337
in colitis, 1351
in colon, 1225–1226, 1267–1268, 1347–1351
in Dieulafoy's lesion, 1332–1333
in diverticula, 1350

Bleeding, gastrointestinal (*continued*)
in esophageal varices, 1337–1343
in gastric varices, 1344
in Mallory-Weiss tears, 1333–1334
in peptic ulcer disease. *See* Peptic ulcer disease, bleeding in.
in rectum, 1221
in small intestinal disorders, 1336–1337, 1344–1347
in vascular ectasia, 1334–1336
initial approach in, 1319–1320
mechanical methods for, 1328
retreatment in, 1332
safety of, 1332
sclerotherapy, 1325–1327
sonographic-guided injections, 1307
stigmata of, 1320–1322
thermally active methods for, 1322–1325, 1327–1328
in colonoscopy, 1271, 1273–1274
in esophagogastroduodenoscopy, 1201
in peptic ulcer disease. *See* Peptic ulcer disease, bleeding in.
interventional radiology in, 1357–1376
angiography, 1359–1365
colonic varices and hemangiomas, 1367–1374
in chronic bleeding, 1374–1376
initial management, 1358
lower, 1365–1376
panendoscopy, 1359
upper, 1358–1365

Bloating, in irritable bowel syndrome, 1529

Blocking antibody, in asthma, immunotherapy effects on, 1094–1096

Blood disorders, in Chinese medicine, 67

Blood transfusions, Jehovah's Witnesses beliefs on, 876–877

Body fluids, balance/imbalance of, in Chinese medicine, 67–68

Body louse, relapsing fever transmitted by. *See* Relapsing fever, tick-borne or louse-borne.

Borrelia
antigenic variation in, 324, 423
relapsing fever caused by. *See* Relapsing fever, tick-borne or louse-borne.

Borrelia burgdorferi. See also Lyme disease.
antibiotic minimal inhibitory concentrations for, 345
antigens of, 274
characteristics of, 262–263, 312–313
genospecies of, 262–263
recombinant chimeric proteins of, in Lyme disease testing, 267
surface proteins of, gene expression alterations in, 221
tick interactions with, 221

Borrelia duttonii, relapsing fever caused by, 420

Borrelia hermsii, relapsing fever caused by, 420–422, 427

Borrelia parkeri, relapsing fever caused by, 420, 423

Borrelia recurrentis, relapsing fever caused by, 420

Borrelia turicatae, relapsing fever caused by, 420, 422, 427

Botulinum toxin injection, for achalasia, endoscopic ultrasonography with, 1307

Bovine spongiform encephalopathy, transmission of, 553

Bowel preparation, for colonoscopy, 1234–1235

Bradykinesia, in dementia with Lewy bodies, 524–525

Brain
dysfunction of, in irritable bowel syndrome, 1530–1531
mild injury of, homeopathy for, 57

Breast cancer, massage therapy for, 168–169

Breathing
in imminent death, 764
postoperative exercises for, 743

Bronchitis, occupational, 966

Bronchoconstriction, leukotriene modifier effects on, 1014–1016

Bronchodilators
for asthma
beta-agonist. *See* Beta-agonists, occupational, 968
for chronic obstructive pulmonary disease exacerbations, 817

Budesonide
for inflammatory bowel disease, 1502
inhaled, for asthma. *See* Corticosteroids, for asthma, inhaled.

Building-related illness, 965, 967

Bull's eye rash. *See* Erythema migrans.

C

CADASIL (cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy)
diagnosis of, 485
genetics of, 598–599

Calcium channel blockers
for irritable bowel syndrome, 1539
for vascular dementia, 490

Callister bactericidal assay, for Lyme disease, 330–331

Cancer
breast, massage therapy for, 168–169
colorectal. *See* Colorectal cancer.
esophageal. *See* Esophagus, cancer of.
gastric
endoscopic ultrasonography in, 1297
esophagogastroduodenoscopy in, 1200–1201
laparoscopic surgery in, 1412–1413
guided imagery for, 21–22, 117–118
lung, metastatic to mediastinal lymph nodes, endoscopic ultrasonography in, 1301–1302
rectal. *See also* Colorectal cancer.
endoscopic ultrasonography in, 1304
relaxation therapy for, 26
small intestinal, endoscopic diagnosis and therapy of, 1336–1337
staging of, endoscopic ultrasound for, 1292

Candidiasis
esophageal,
esophagogastroduodenoscopy in, 1195
in inhaled corticosteroid therapy, 1043

Capacity, for decision-making, 874–875

Carbamazepine, for pain, 788

Carbohydrates, malabsorption of, irritable bowel syndrome in, 1533–1534

Carcinoid tumor, colonic
bleeding from, interventional radiology in, 1371
colonoscopy in, 1264

Cardiac arrhythmias
in colonoscopy, 1270–1271
in Lyme disease, 288–290

Cardiomegaly, in Lyme disease, 290–291

Cardiovascular system
beta-agonist effects on, 994
opioid effects on, 781
preoperative assessment of, 735–737, 799–800

Carditis, Lyme, **285–296**
clinical features of, 287–291
conduction disease in, 288–290
diagnosis of, 291–292
epidemiology of, 285–286
mouse models for, 287
myocardial disease in, 290–291
pathology of, 286–287
treatment of, 292–293

Caregivers, for dementia patients, behavioral strategies for, 642–649

Carpal tunnel syndrome, manipulation techniques for, 94–95

Carpets
house dust mite allergen removal from, 978
pet allergen removal from, 980

Cat allergens, environmental controls for, 979–981

Cataracts, in inhaled corticosteroid therapy, 1042–1043

Cathartic colon, colonoscopy in, 1266

Caustic enemas, colonoscopy in, 1259

Caustic ingestion,
esophagogastroduodenoscopy in, 1175

CD 23 inhibitors, for asthma, 1135

CDP 571, for inflammatory bowel disease, 1507–1508

CDP840 phosphodiesterase inhibitor, for asthma, 1140

Cecum, volvulus of,
colonoscopy in, 1269

Cefotaxime, for Lyme disease, 270, 305

Ceftriaxone, for Lyme disease, 270–271
chronic, 346–347
in carditis, 292

Cefuroxime, for Lyme disease, 270
chronic, 346
in arthritis, 305
in erythema migrans, 256

Celecoxib, for pain, 787

Celiac disease,
esophagogastroduodenoscopy in, 1196–1197

Celiac plexus neurolysis, endoscopic ultrasonography in, 1306

Cell(s), inflammation of, in asthma, 926

Cellulitis, versus erythema migrans, 251–252, 257

Central nervous system
dysfunction of, in irritable bowel syndrome, 1530–1531
opioid effects on, 781

Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL)
diagnosis of, 485
genetics of, 598–599

Cerebrospinal fluid, analysis of
in dementia, 461, 542–543
in Lyme disease, 269, 331–332

Cetirizine, for asthma, leukotriene modifiers with, 1024

Chakra therapies, 114–115

Challenge testing, in occupational asthma, 963–964

Channels, in Chinese medicine, 64–65

Chemicals, occupational asthma induced by, 958–959

Chemokines, in asthma
from mast cells, 926–927
inhibitors of, 1140–1141

Chemotherapy
guided imagery with, 21–22
vomiting in, in end-of-life care, 762–763

Chest radiography, in asthma, 961, 963

Chest tubes, for malignant pleural effusions, 814–815

Chinese herbs nephropathy, 159

Chinese medicine, traditional, **63–73**
acupuncture in, 70–72, 113, 176
basis of, 64–65
blood disorders in, 67
body fluid imbalance in, 67–68
diagnosis in, 68–70
energy *(qi)* principle in, 64, 66–67
English translation problems in, 63–64
herbology in, 72
history of, 63–64
methods used in, 65
philosophy of, 66
quality of preparations for, 158–159
training for, 71
versus Western allopathic medicine, 65–66

Chiropractic care, 91, 99–100
network, 111–113

Chloramphenicol
for ehrlichiosis, 385
for relapsing fever, 429
for Rocky Mountain spotted fever, 357–358
for tularemia, 402–403

Chloroquine, for babesiosis, 368–369

Chlorpheniramine, for asthma, leukotriene modifiers with, 1024

Cholecystectomy, laparoscopic, 1402–1406

Choledocholithiasis, endoscopic ultrasonography in, 1299

Choledochotomy, laparoscopic, 1406–1408

Cholesterol levels, transcendental meditation effects on, 14

Cholinergic system defects
in Alzheimer's disease, 657
in dementia with Lewy bodies, 526–527, 529

Cholinesterase inhibitors. *See also specific agents.*
for Alzheimer's disease, 657–664
for vascular dementia, 491–492

Chorea, in Huntington's disease, 599

Chromium, supplementary, 132

Chromosomal instability, in colorectal cancer, 1468–1469

Chronic fatigue syndrome
manipulation techniques for, 95
versus Lyme disease, 343

Chronic obstructive pulmonary disease
beta-agonists for, 1004
exacerbations of, management of, 815–817

Ciliary action, beta-agonist effects on, 993

Cilostazol, for asthma, 1140

Ciprofloxacin, for inflammatory bowel disease, 1502–1503

Cisapride, for irritable bowel syndrome, 1541

Citicoline, for vascular dementia, 490

Cladosporium allergens, environmental controls for, 984–986

Clarithromycin, for *Helicobacter pylori* infection, 1459–1460

Clindamycin, for babesiosis, 368–369

Clostridium difficile colitis, colonoscopy in, 1257

Clozapine, for dementia with Lewy bodies, 528

Cockroach allergens, environmental controls for, 981–983

Codeine, for pain, 783

Coenzyme Q_{10}, as dietary supplement, 137–138

Cognitive-behavioral therapy
for irritable bowel syndrome, 1543
for pain, 792
hypnosis with, 19–20

Cognitive dysfunction
in dementia
AIDS, 539
evaluation of, 456–457
versus normal aging, 461–462
with Lewy bodies, 522–523
in Huntington's disease, 599
mild, versus dementia, 462–463
of elderly persons, in hospital, 713–717

Cold syndrome, in Chinese medicine, 69

Colectomy
for familial adenomatous polyposis, 1483
for hereditary nonpolyposis colorectal cancer, 1478

Colitis
bacterial, colonoscopy in, 1257
bleeding in, endoscopic diagnosis and therapy of, 1351
collagenous, colonoscopy in, 1259
ischemic, 1261–1262, 1384–1385
lymphocytic, colonoscopy in, 1259
pseudomembranous, colonoscopy in, 1257
radiation, colonoscopy in, 1259
ulcerative. *See* Ulcerative colitis.

Colitis cystica profunda, sigmoidoscopy in, 1255

Collagenous colitis, colonoscopy in, 1259

Colon
angiodysplasia of
colonoscopy in, 1259–1260
endoscopic diagnosis and therapy of, 1350
interventional radiology in, 1371
bleeding in
diverticular, 1266–1267, 1350, 1371
endoscopic diagnosis and therapy of, 1347–1350
interventional radiology in, 1367–1374
carcinoid tumor of, colonoscopy in, 1264
cathartic, colonoscopy in, 1266
decompression of, colonoscopy in, 1268–1269
diverticula of
bleeding from
colonoscopy in, 1266–1267
endoscopic diagnosis and therapy of, 1350
interventional radiology in, 1371
colonoscopy in, 1241–1242
endoscopic ultrasonography of, 1304
Henoch-Schonlein purpura of, colonoscopy in, 1267
intussusception of, colonoscopy in, 1267
laparoscopic resection of, 1417
lipoma of, colonoscopy in, 1263–1264
lymphoma of, colonoscopy in, 1265
melanosis of, colonoscopy in, 1265
motility disorders of, in irritable bowel syndrome, 1528–1529
obstruction of, colonoscopy in, 1230–1231
perforation of, in colonoscopy, 1271, 1273
phlebectasia of, colonoscopy in, 1261
polyps of, colonoscopy in, 1262–1264, 1269–1270
stercoral ulcer of, colonoscopy in, 1266
stricture of, colonoscopy in, 1264–1265, 1268
tumors of. *See also* Colorectal cancer.
bleeding in, endoscopic diagnosis and therapy of, 1351
colonoscopy in, 1263–1265
varices of, colonoscopy in, 1262
vascular lesions of, colonoscopy in, 1259–1262
volvulus of, colonoscopy in, 1269

Colonoscopy, **1217–1252**
adjunct medications for, 1237
alternatives to, 1275–1276
anesthesia for, 1236–1237
biopsy in, 1238, 1243
cecal intubation in, 1241–1242
colonic preparation for, 1234
complications of, 1231, 1270–1275
contraindications for, 1231–1232
cost considerations in, 1228–1229
equipment for, cleaning of, 1275
historical background of, 1217–1219
in bleeding, 1347–1350

Colonoscopy (*continued*)
therapeutic, 1267–1268
versus angiography, 1372
in cathartic colon, 1266
in colitis, 1256–1259
in colorectal cancer, 1264–1265
hereditary nonpolyposis, 1226–1227, 1477–1478
in Crohn's disease, 1256–1257
in decompression, 1268–1269
in ischemic colitis, 1385–1386
in pediatric patients, 1238–1239
in pneumatosis coli, 1266
in polyps, 1262–1264
in stercoral ulcers, 1266
in stricture, 1264–1265, 1268
in ulcerative colitis, 1256
in vascular lesions, 1259–1262
in volvulus, 1269
indications for, 1223–1228
in higher risk patients, 1228–1231
instruments for, 1238–1239
magnification in, 1279
monitoring in, 1235
open access, 1232, 1276
preprocedure evaluation and instructions for, 1232–1234
retroflexion in, 1242
sedation for, 1235–1236
technique for, 1239–1243
therapeutic, 1267–1270
virtual, in colorectal cancer screening, 1472–1473

Colopathy, portal, colonoscopy in, 1262

Colorado tick fever
clinical features of, 437
complications of, 437
diagnosis of, 437–438
epidemiology of, 436
pathogenesis of, 435–436
treatment of, 438
vectors for, 434
viral cause of, 435–436

Colorectal cancer
bleeding in, interventional radiology in, 1372
colonoscopy in, 1264–1265
genetics of, **1467–1495**
attenuated familial adenomatous polyposis, 1485
familial adenomatous polyposis, 1479–1485
hamartomatous polyposis syndrome, 1486–1487
hereditary nonpolyposis, 1474–1479
sporadic, 1467–1473
Turcot's syndrome, 1485
screening for, 1276–1278, 1472–1473
colonoscopy in, 1226
in familial adenomatous polyposis, 1483
sigmoidoscopy for, 1222

Common bile duct, laparoscopic exploration of, 1406–1408

Common cold, echinacea for, 134–135

Communication
about complementary medicine. *See* Complementary and alternative medicine, talking with patients about.
in hospital medicine, 899–903
in end-of-life care, 751–753, 812–814

Compensation, in occupational asthma, 969–970

Competency, for decision-making, 874–875

Complementary and alternative medicine
Ayurvedic, **75–89**
Chinese. *See* Chinese medicine.
definition of, 1
dietary supplements in, **127–147,** 176
energy, **105–125**
for irritable bowel syndrome, 1544
herbal. *See* Herbal medicine.
homeopathy in, **47–62,** 176
legal issues in, **185–196**
magnitude of, 1–2
manual and manipulative, **91–103**, 176
massage therapy in, 97–98, **163–171**
mind-body medicine, **11–31**
naturopathy in, **173–184**
prayer and spirituality in. *See* Prayer, in health care.
reasons for using, 3
talking with patients about, **1–9**
reasons for, 4–5
reluctance to, 3–4
techniques for, 5–7
users of, 2–3

Computed tomography
in dementia, 460–461
in ischemic colitis, 1385
in mesenteric ischemia, 1378–1379
chronic, 1387
in venous thrombosis, 1384
in pulmonary embolism, 811–812

Concentration response, in meditation, 15–16

Conduction disturbances, in Lyme disease, 288–290

Condyloma acuminata, rectal,
sigmoidoscopy in, 1255

Confidentiality, 875–876, 878–879

Congestive heart failure
coenzyme Q_{10} for, 137–138
in Lyme disease, 290–291

Consciousness
alterations of, in transcendental meditation, 13–15
nonlocal, 108–109, 119–120

Constipation
biofeedback for, 24
in end-of-life care, 761
in irritable bowel syndrome, 1527
hormonal factors in, 1534
laxatives for, 1538, 1541
motility patterns in, 1528–1529
treatment of, 1538, 1541–1542, 1544–1545
opioid-induced, 781

Consultation, in perioperative management, 733–734

Contact dermatitis, versus erythema migrans, 252, 254

Coronary artery disease
omega-3 fatty acids and, 139
prayer for, 38–39

Corticobasal degeneration, 508–509

Corticosteroids
for asthma
acute severe, 1057–1058
beta-agonists with, 993–994, 999, 1002, 1041–1043
inhaled, **1035–1048**
adherence issues in, 1045
beta-agonists with, 1041–1043
clinical considerations in, 1045
clinical effectiveness of, 1039–1041
complications of, 1043–1045
dose-response relationships of, 1037–1039
for acute severe attacks, 1061–1062
importance of, 1035–1036
mechanisms of action of, 1036–1037
oral dose reduction in, 1040
time-response relationships of, 1037
versus leukotriene inhibitors, 1040–1041
leukotriene modifiers with, 1020–1023
mechanisms of action of, 1079–1081
occupational, 965, 968
refractory, 1085
resistance to, 1079–1084
for chronic obstructive pulmonary disease exacerbations, 817
for inflammatory bowel disease, 1502

Cough syrups, for asthma, 1063

Coxiella burnetii infection. *See* Q fever.

CpG DNA motifs, immunotherapy based on, for asthma, 1144–1145

Cranial nerve palsy, in Lyme disease, 266

Craniosacral osteopathy, 111–113

Creutzfeldt-Jakob disease, 551–552
clinical features of, 469–470
genetics of, 605–607
variant (mad cow disease), 605
diagnosis of, 567–568
rise of, 562–564
surveillance for, 567–568
transmission of, 553
versus Creutzfeldt-Jakob disease, 563

Crohn's disease
adhesion molecule inhibitors for, 1511
aminosalicylates for, 1500–1501
antibiotics for, 1502–1503
bleeding in, interventional radiology in, 1372
colonoscopy in, 1256–1257
colony-stimulating factors for, 1511–1512
corticosteroids for, 1502
cytokine mediators for, 1510
diagnosis of, 1499–1500
endoscopic diagnosis and therapy of, 1303, 1337
genetics of, 1497–1498
immunomodulators for, 1503–1505
omega-3 fatty acids for, 139
tumor necrosis factor inhibitors in, 1505–1510

Cromoglycate, for irritable bowel syndrome, 1542

Cultivation, of *Borrelia burgdorferi*, 316–317

Cultural issues
in end-of-life care, 766
organizational, in quality improvement, 840–841

Culture, *Helicobacter pylori*, 1457–1458

Cyanoacrylate, injection of, for esophageal varices, 1343

Cyclosporine A
for asthma, 1086
for inflammatory bowel disease, 1504–1505

Cytokines
at low concentrations, biologic activity of, 50
for asthma treatment
in immunotherapy, 1145
peglyation of, 1146
in asthma pathogenesis, 1093–1094, 1114–1116, 1132
beta-agonist effects on, 993
from macrophages, 929–930
from mast cells, 926–927
from T lymphocytes, 929
genetic aspects of, 945–947
immunotherapy effects on, 1098
inhibitors of, 1135–1140
leukotriene modifier effects on, 1010, 1013
in atopy, genetic aspects of, 941–943

Cytomegalovirus infections
colitis, colonoscopy in, 1258
esophageal,
esophagogastroduodenoscopy in, 1195

D

D-dimer assay, for pulmonary embolism diagnosis, 807–811

Data transmission, ethical issues in, 877–881

DCC gene, mutations of, in colorectal cancer, 1470

Death. *See* End-of-life care.

Death certificate, 768–769

Death rattle, management of, 764

Decision making
capacity and competency for, 874–875
in end-of-life care, 751–757

Deep syndrome, in Chinese medicine, 69

Deer-fly fever. *See* Tularemia.

Deer tick. *See Ixodes scapularis.*

DEET, as tick repellent, 226

Deficiency syndrome, in Chinese medicine, 69–70

Dehydration, in elderly persons, in hospital, 722

Delavirdine, for AIDS dementia, 545

Delirium
in hospital
in elderly persons, 713–717
in end-of-life care, 763
postoperative, 739–741
versus dementia, 463

Dementia(s)
Alzheimer's. *See* Alzheimer's disease.
behavioral disturbances in. *See* Behavioral disturbances, in dementia.
causes of, 464–472, 575–578
definition of, 456
diagnosis of, **455–476**
clinical evaluation in, 456–460
for epidemiologic studies, 573–574
laboratory tests in, 461
neuroimaging in, 460–461
differential diagnosis of, 461–464, 577–578
epidemiology of, 455, **573–590**. *See also specific forms of dementia.*
frontotemporal. *See* Frontotemporal dementia.
genetics of. *See* Genetic factors, in dementia.
in Binswanger's disease, 598
in chronic subdural hematoma, 469
in elderly persons, in hospital, 715
in end-of-life care, 814
in HIV infection, **537–550**
in Huntington's disease, 599–600
in hydrocephalus, 471–472
in infections, 469–470. *See also* AIDS dementia; Prion diseases.
in metabolic disease, 470–471
in mitochondrial disorders, 608
in parkinsonism, 467–469
in prion diseases, **551–571**, 604–607
semantic, 507–508
subcortical, 483–484
toxin-related, 470
treatment of. *See also specific forms of dementia.*
nonpharmacologic, **639–654**
pharmacologic, **655–672**
vascular. *See* Vascular dementia.
with Lewy bodies, **519–535**
diagnosis of, 467–469, 522–526
differential diagnosis of, 578
epidemiology of, 578
genetics of, 530, 597
historical perspective of, 519–522
neurochemistry of, 529–530

pathology of, 520–522
pathophysiology of, 529
research on, 528–530
treatment of, 526–528, 666–667

Dependence, on opioids, 790–791

Depression
in hospital
in elderly persons, 717
in end-of-life care, 763
massage therapy for, 166
relaxation therapy for, 26
St. John's wort for, 135–136
versus dementia, 463
with dementia, 644–645

Dermacentor andersonii (wood tick), in disease transmission
Colorado tick fever, 436
Rocky Mountain spotted fever, 352
tick paralysis, 441–442

Dermacentor variabilis (dog tick)
attachment of
duration of, 227
sites of, 223
in disease transmission
ehrlichiosis, 377
Rocky Mountain spotted fever, 352
tick paralysis, 441–445
morphology of, 245
natural history of, 214–215

Dermatitis, contact, versus erythema migrans, 252, 254

Desmoid tumors, in familial adenomatous polyposis, 1482–1483

Devil's claw, drug interactions with, 156–157

Dextroamphetamine, in end-of-life care
for depression, 763
for pain, 761

Diabetes mellitus, massage therapy for, 169–170

Diarrhea
colonoscopy in, 1226
esophagogastroduodenoscopy in, 1177–1178, 1196–1198
homeopathy for, 57
in irritable bowel syndrome, 1527
hormonal factors in, 1534
in malabsorption, 1533–1534
motility patterns in, 1528–1529
treatment of, 1538–1541, 1545
sigmoidoscopy in, 1220

Didanosine, for AIDS dementia, 545

Dietary supplements, **127–147**
S-adenosyl-L-methionine, 138
coenzyme Q_{10}, 137–138
fiber, for irritable bowel syndrome, 1537–1538
herbal. *See* Herbal medicine.
in naturopathy, 176
minerals, 132–133
misinformation on, 129
necessity of, 128–129
omega-3 fatty acids, 139–140
safety of, 129
studies on, problems with, 127–128
vitamins, 130–131

N,N-Diethyl-m-toluamide (DEET), as tick repellent, 226

Dieulafoy's lesion
bleeding in
angiography in, 1361–1362
endoscopy in, 1332–1333
colonoscopy in, 1260
esophagogastroduodenoscopy in, 1189–1190

Diffuse idiopathic skeletal hyperostosis, manipulation techniques for, 95

Dilutions, high, in homeopathy, 51–52

Diphenhydramine, for vomiting, in end-of-life care, 762–763

Disability, in occupational asthma, 969–970

Discharge planning
communication in, 900–901
for elderly persons, 723–724
in quality improvement program, 842–844

Disinhibition, in frontotemporal dementia, 505–506

Diverticulum
colonic
bleeding from
colonoscopy in, 1266–1267
endoscopic diagnosis and therapy of, 1350
interventional radiology in, 1371
colonoscopy in, 1241
Meckel's
laparoscopic resection of, 1415
nuclear bleeding scan in, 1375–1376

DNA vaccines, for asthma, 1145

Do-not-attempt-resuscitation orders, 753–754

Docusate sodium, in end-of-life care, 761

Dog allergens, environmental controls for, 979–981

Dog tick. *See Dermacentor variabilis.*

Donepezil
for Alzheimer's disease, 659–660, 663–664
for dementia with Lewy bodies, 527
for vascular dementia, 491–492

Dong quai, drug interactions with, 157

Dopaminergic system defects, in dementia with Lewy bodies, 529

Doppler studies, in mesenteric ischemia, chronic, 1387

Dor fundoplication, laparoscopic, 1411

Dosha, in Ayurvedic medicine, 76–82, 85–86

"Double effect" opioids, in end-of-life care, 758

Down's syndrome, Alzheimer's disease-like pathology in, 633

Doxycycline
for ehrlichiosis, 385
for Lyme disease, 270–271
chronic, 345–347
in arthritis, 305
in carditis, 292
in erythema migrans, 255–256
for Q fever, 412–413
for relapsing fever, 429
for Rocky Mountain spotted fever, 356–357
for tick bites, 228

Dressler's criterion, for Western blot test, in Lyme disease, 328–330

Drotrecogin alfa, for sepsis, 805–807

Drug(s)
abuse of, transcendental meditation for, 14
adverse reactions to, in elderly persons, 718–720
delirium induced by, 740–741
in Ayurvedic medicine, 81–83
pharmacokinetics of, in pain management, 778–780

Drug eruptions, versus erythema migrans, 253

Dry powder inhalers, for beta-agonist delivery, in asthma, 996–997

Drying, in Ayurvedic medicine, 81

Duke Activity Status Index, in preoperative evaluation, 734–735

Duodenum
adenocarcinoma of, in familial adenomatous polyposis, 1482
angiodysplasia of, esophagogastroduodenoscopy in, 1190–1191
endoscopy of. *See* Esophagogastroduodenoscopy.
peptic ulcer disease of. *See* Peptic ulcer disease.
vascular ectasia of, endoscopic diagnosis and therapy of, 1334–1336

Dust mite allergens, environmental controls for, 976–979

Dying patient care. *See* End-of-life care.

Dysexecutive syndrome, 506

Dyspepsia
esophagogastroduodenoscopy in, 1175
in peptic ulcer disease, 1455

Dysphagia
after fundoplication, 1411
esophagogastroduodenoscopy in, 1173–1174, 1194–1196

Dysphonia
in inhaled corticosteroid therapy, 1043
in refractory asthma, 1077–1078

Dyspnea, in end-of-life care, 761–762

E

Echinacea, 134–135
perioperative care and, 801

Economic issues
ethical issues conflicting with, 883–884
hospitalists impact on, 697–702
in hospitalist program organization, 893, 903–906

Edema, lymphatic massage in, 98

Efavirenz, for AIDS dementia, 545–546

Effleurage, 97, 164

EGB 761 (ginkgo biloba extract), for Alzheimer's disease, 665–666

Ehrlichiosis, **375–392**
clinical features of, 243, 381–382
definition of, 375–376
epidemiology of, 376–378
granulocytotropic, 387
clinical features of, 382
epidemiology of, 376–377
historical background of, 375
in tick-borne coinfections, 277–278, 382

laboratory testing for, 382–384
microbiology of, phylogeny of, 376
monocytotropic, 387
clinical features of, 381–382
epidemiology of, 377–378
new form of (*Ehrlichia eweingii*), 386–387
pathogenesis of, 378–380
pathology of, 380–381
prognosis for, 386
treatment of, 385–386
vectors for, 377–378

Elderly persons, hospital medicine for, **709–731**
demographics of, 710
discharge from, 723–724
future of, 726–727
hazards of, 712–722
dehydration, 722
delirium, 713–717
dementia, 715
depression, 717
functional decline, 712–713
iatrogenic illness, 718–720
immobility, 713
incontinence, 721
malnutrition, 722
pressure ulcers, 721–722
restraints, 717–718
home-based, 726–727
indications for admission, 711–712
individual treatment plan in, 723
interdisciplinary teamwork in, 723–724
objectives of, 710
outcomes of, 725–726
perioperative complications in, 802–803
quality of care in, 722–724
readmission incidence and, 710–711
specialized models for, 725–726
transitional care and, 724–725
treatment goals in, 723

Electrocoagulation
for colonic bleeding, 1348–1349
for peptic ulcer bleeding, 1324–1325

ELISA. *See* Enzyme-linked immunosorbent assay.

Emancipation, of minors, informed consent for, 874

Embolism, pulmonary, diagnosis of, 807–811

Embolotherapy, for gastrointestinal bleeding, 1364–1365, 1373

Encephalitis, flavivirus, in tick-borne coinfections, 277–278

Encephalopathy
in Lyme disease, 266
transmissible spongiform. *See* Prion diseases.
Wernicke's, 470

End-of-life care, **751–772**
advance directives for, 753
after death, 768–770
autopsy request in, 769
communication in, 812–814
cultural issues in, 766
death certificate in, 768–769
decision making at, 751–757
dementia in, 814
do-not-attempt-resuscitation orders in, 753–754
"double effect" opioids in, 758
ethical issues in, 757–758
family meetings and support in, 755–757, 769–770
futility dilemmas in, 757–758
grief management in, 765
hope in, 755
hospice, 766–767
hospitalists self-care and, 770
imminent death in, 764
in Ayurvedic medicine, 80–81
in intensive care unit, 767–768
legal issues in, 757–758
nutrition in, 764
prognosis discussion in, 754–755
spiritual issues in, 766
symptom management in, 758–764
death rattle, 764
delirium, 763
depression, 763
dyspnea, 761–762
nausea and vomiting, 762–763
pain, 758–761
updates on, 812–817
withholding and withdrawing life sustaining measures in, 758

Endemic relapsing fever. *See* Relapsing fever, tick-borne or louse-borne.

Endocarditis
in Q fever, 409–413
prophylaxis for
in colonoscopy, 1233–1234
in esophagogastroduodenoscopy, 1170

Endoluminal laparoscopic surgery, 1419

Endorphins, release of, in acupuncture, 70

Endoscopy, gastrointestinal. *See also* Esophagogastroduodenoscopy; Colonoscopy; Sigmoidoscopy.
in bleeding. *See* Bleeding.

Endoscopy (*continued*)
gastrointestinal, endoscopic diagnosis and therapy of,
of small intestine, 1375
ultrasonography in, **1289–1317**
upper, in peptic ulcer, 1455

Endothelial adhesion molecules, inhibitors of, for asthma, 1142

Endothelial cells, beta-agonist effects on, 993

Enemas, caustic, colonoscopy in, 1259

Energy medicine, **105–125**
acupuncture in, 70–72, 113, 176
applied kinesiology in, 113–114
background of, 105–107
certification for, 120
craniosacral osteopathy in, 111–113
definition of, 105
experiential exercise in, 121
eye movement desensitization and reprocessing in, 115–116
flower essences in, 116–117
imagery in, 21–23, 117–118
integrative care in, 109
intuitive assessments and interventions in, 119–120
meditation in, 12–18, 118–119
meridian-based therapies in, 64, 114–115
modalities in, 106
network chiropractic in, 111–113
practitioners of, selection of, 121
safety of, 120
spiritual healing in, 110–111. *See also* Prayer, in health care.
theory of, 107–109

Energy (*qi*) principle, in Chinese medicine, 64, 66–67

Enteroscopy, in small intestinal bleeding, 1345–1346, 1375
wireless capsule, 1346–1347

Environmental controls, for asthma, **973–989**
air sampling methods for, 974
cockroach allergens, 981–983
fungal allergens, 983–986
house dust mite allergens, 976–979
pet allergens, 979–981
threshold levels and, 974–975

Environmental factors, in peptic ulcer disease, 1451–1452

Enzyme-linked immunosorbent assay
for Lyme disease, 267, 325–327, 344
for tick-borne relapsing fever, 428

Eosinophils, in asthma, 927–928

Ephedra, perioperative care and, 801

Epigastric pain,
esophagogastroduodenoscopy in, 1192–1194

Epigenetic processes, in colorectal cancer, 1471–1472

Epinephrine
for asthma, 998, 1001, 1062
injection of, for peptic ulcer bleeding, 1327–1328, 1331

Epithelial cells, in asthma, 930

Errors. *See* Medical errors.

Erythema migrans, **239–260**
clinical manifestations of, 243–250, 264–265
diagnosis of, 250–251
differential diagnosis of, 251–254
epidemiology of, 242–243
evolution of, 247
historical perspective of, 240
in pediatric patients, 276
location of, 244
morphology of, 247–249, 265
multiple, 248–249, 341
non-Lyme disease, 324–325
pathogenesis of, 240–242
size of, 244, 247
skin biopsy in, laboratory testing of, 316
symptoms associated with, 243–244
treatment of, 255–257
outcome of, 257–258
with diagnostic uncertainty, 254–255

Erythema multiforme, versus erythema migrans, 253

Erythrocytes, babesiosis of, 367–368

Erythromycin
for Lyme disease, 270
for Q fever, 412
for relapsing fever, 429

Esophagectomy, for Barrett's esophagus, 1432, 1435–1437

Esophagogastroduodenoscopy, **1165–1216**
anesthesia for, 1182–1184
complications of, 1201–1203
contraindications to, 1179–1181
equipment for, 1167, 1169
cleaning of, 1203
future potential of, 1203–1204
historical background of, 1165–1168
in abdominal pain, 1175

in abetalipoproteinemia, 1197–1198
in abnormal radiographic findings, 1178–1179
in anastomotic ulcers, 1191
in angiodysplasia, 1190–1191
in aortoenteric fistula, 1192
in asymptomatic lesions, 1187–1188
in Barrett's esophagus, 1198
in bezoars, 1187–1188
in bleeding, 1171, 1173, 1188–1192
in cancer, 1200–1201
in caustic ingestion, 1175
in celiac disease, 1196–1197
in diarrhea, 1177–1178, 1196–1198
in Dieulafoy lesion, 1189–1190
in dyspepsia, 1175
in dysphagia, 1173–1174, 1194–1196
in gastric atrophy, 1198
in gastric polyps, 1198–1199
in gastritis, 1188
in gastroesophageal reflux disease, 1192–1193
in giardiasis, 1197
in hemangioma, 1191
in hemobilia, 1192
in hiatal hernia, 1187
in human immunodeficiency virus infection, 1197
in infections, 1195–1196
in Kaposi's sarcoma, 1192
in lymphoma, 1200–1201
in malabsorption, 1177–1178, 1196–1198
in malignant lesions, 1200–1201
in Mallory-Weiss tear, 1189
in mobility disorders, 1194–1195
in nausea and vomiting, 1174–1175
in odynophagia, 1194–1196
in pain, 1192–1194
in portal gastropathy, 1189
in premalignant lesions, 1176–1177, 1198–1200
in pyrosis, 1175
in rings, 1195
in stress-related gastric injury, 1190
in strictures, 1195
in thickened gastric folds, 1199–1200
in ulcers, 1193–1194
in varices, 1188–1189
in vascular ectasia, 1191–1192
in webs, 1195
in Whipple's disease, 1197
indications for, 1171–1179
monitoring in, 1181–1182
preprocedure evaluation and instructions for, 1169–1171
sedation for, 1182
technique for, 1181–1187

Esophagogastrostomy, for Barrett's esophagus, 1437

Esophagomyotomy, laparoscopic, 1409–1410

Esophagoscopy, in Barrett's esophagus surveillance, 1430–1432, 1438

Esophagus
achalasia of
botulinum toxin injection for, endoscopic ultrasonography with, 1307
esophagogastroduodenoscopy in, 1176, 1194
Barrett's. *See* Barrett's esophagus.
bleeding in, angiography for, 1363
cancer of
endoscopic ultrasonography in, 1295
esophagogastroduodenoscopy in, 1200–1201
in Barrett's esophagus
dysplasia and, 1433–1438
incidence of, 1430–1432
metastasis from, 1438
risk reduction for, 1427–1430
surveillance for, 1430–1432
candidiasis of,
esophagogastroduodenoscopy in, 1195
laparoscopic surgery of, 1408–1412
esophagomyotomy, 1409–1410
fundoplication, 1410–1411
paraesophageal hernia repair, 1411
resection, 1412
premalignant lesions of,
esophagogastroduodenoscopy in, 1176–1177
resection of, laparoscopic, 1412
rings in, esophagogastroduodenoscopy in, 1195
stricture in,
esophagogastroduodenoscopy in, 1195
varices of
banding for, 1341–1343
combination sclerotherapy and ligation for, 1343
diagnosis of, 1339
endoscopic diagnosis and therapy of, 1307, 1339–1343
esophagogastroduodenoscopy in, 1188–1189
pharmacologic therapy for, 1338
polymer injection for, 1343
sclerotherapy for, 1339–1341
webs in,

Esophagus (*continued*)
esophagogastroduodenoscopy in, 1195

Etanercept, for inflammatory bowel disease, 1508–1509

Ethanol, for sclerotherapy, in peptic ulcer bleeding, 1327

Ethical issues, in hospital medicine, **871–888**
capacity, 874–875
competency, 874–875
confidentiality, 875–876, 878–879
economic incentives conflicting with, 883–884
in end-of-life care, 757–758
in hospitalist model, 881–884
informatics and, 877–881
informed consent, 872–874
Jehovah's Witnesses and, 876–877
medical errors, 884–886
principles of, 871–872
professionalism, 885–886
restraints, 877
terminology of, 871
truth, 884–886

Ethnomedical validation, 86

Evening primrose oil
drug interactions with, 157
efficacy of, 154–155

Excess syndrome, in Chinese medicine, 69–70

Exercise
asthma induced by
beta-agonists for, 1003
leukotriene modifiers for, 1024–1025
for muscle pain, 96

Extermination, of cockroach population, in asthma, 982–983

Extrapyramidal features, in Pick's disease, 503

Eye, tularemia manifestations in, 399

Eye movement desensitization and reprocessing, 115–116

Eyebright, in homeopathy, 54

F

Facial nerve palsy, in Lyme disease, 276

Facsimile devices, patient information transmission through, 879–880

Familial adenomatous polyposis, 1479–1485
attenuated, 1485
clinical manifestations of, 1481
colonoscopy in, 1263
diagnosis of, 1483
extraintestinal features of, 1482–1483
genetics of, 1480–1481
genotype-phenotype correlations in, 1483–1485
incidence of, 1479
treatment of, 1483–1484
upper gastrointestinal tumors in, 1481–1482
variants of, 1485

Familial dementias
Alzheimer's, 582–583, 592–597, 615–627, 630–637
fatal familial insomnia, 551–552, 605
frontotemporal, 602–603

Family
communication with, 902–903
in end-of-life care, 755–757, 769–770

Fatty acids, omega-3, as dietary supplements, 139–140

Fear, eye movement desensitization and reprocessing technique for, 115–116

Fecal incontinence, biofeedback for, 24

Fecal occult blood test, versus colonoscopy, 1276–1277

Fedotozine, for irritable bowel syndrome, 1542–1543

Fel d cat allergens, environmental controls for, 979–981

Fentanyl, for pain, 784–785

Feverfew
drug interactions with, 157
efficacy of, 153–154

Fiber, dietary, for irritable bowel syndrome, 1537–1538

Fibroblasts, in asthma, 930

Fibromyalgia
after Lyme disease, 307–308
manipulation techniques for, 95
massage therapy for, 167
osteopathy for, 99
versus Lyme disease, 343

Fibrosis, in asthma, 930–931

Fish oils, omega-3 fatty acids in, 139–140

Fissures, anal, sigmoidoscopy in, 1254

Fistula, aortoenteric
endoscopic diagnosis and therapy of, 1337

esophagogastroduodenoscopy in, 1192

Flavivirus encephalitis, in tick-borne coinfections, 277–278

Flax seed oil, omega-3 fatty acids in, 139–140

Flexible sigmoidoscopy. *See* Sigmoidoscopy.

Flower essences, therapy with, 116–117

Fluid therapy, for asthma, 1060

Flunisolide, inhaled, for asthma. *See* Corticosteroids, for asthma, inhaled.

Fluoroquinolones
for Q fever, 413
for tularemia, 402–403

Fluticasone, inhaled, for asthma. *See* Corticosteroids, for asthma, inhaled.

Food, role of, in irritable bowel syndrome, 1534

Formoterol, for asthma, 998–999, 1001
inhaled corticosteroids with, 1042

Fractures, in inhaled corticosteroid therapy, 1043

Francisella tularensis infection. *See* Tularemia.

Francis's disease. *See* Tularemia.

Frontotemporal dementia, **501–518**
biochemistry of, 511
clinical features of, 501–502, 505–506, 601–602
corticobasal degeneration, 508–509
diagnosis of, 466–467
epidemiology of, 504, 602
genetics of, 511–512, 602–604
historical background of, 501–502
pathology of, 506–507, 510, 602
Pick complex, 509–510
Pick's disease, 502–504, 601
primary progressive aphasia, 507–508
subtypes of, 602
terminology of, 501, 505, 601
treatment of, 512

Functional antibody assays, for Lyme disease, 330–331

Functional decline, of elderly persons, in hospital, 712–713

Functional impairment, in dementia, evaluation of, 457–458

Fundoplication
for Barrett's esophagus, 1429–1430
laparoscopic, 1410–1411

Fungal allergens, environmental controls for, 983–986

Futility dilemmas, in end-of-life care, 757–758

G

Gabapentin, for pain, 788–789

Gait, magnetic, in normal pressure hydrocephalus, 471

Galantamine
for Alzheimer's disease, 662–663
for dementia with Lewy bodies, 527
for vascular dementia, 491–492

Gallbladder
excision of, laparoscopic, 1402–1406
motility disorders of, in irritable bowel syndrome, 1529

Gallstones, retained intraperitoneal, in laparoscopic cholecystectomy, 1405

Gardner's syndrome, 1482

Garlic
as herbal medicine, efficacy of, 154–155
perioperative care and, 801

Gastrectomy, premalignant lesions after, esophagogastroduodenoscopy in, 1177

Gastric antral vascular ectasia, esophagogastroduodenoscopy in, 1191–1192

Gastrinoma
endoscopic ultrasonography in, 1301
in Zollinger-Ellison syndrome, 1194

Gastritis
endoscopic ultrasonography in, 1293
esophagogastroduodenoscopy in, 1177, 1188, 1198

Gastrocolic response, in irritable bowel syndrome, 1528

Gastroesophageal reflux disease
asthma with, 1076–1077
Barrett's esophagus in
pathology of, 1423–1426
treatment of, 1426–1430, 1439–1441
esophagogastroduodenoscopy in, 1192–1193

Gastrointestinal system. *See also specific components, e.g.*, Esophagus.
bleeding in. *See* Bleeding, gastrointestinal.
endoscopy of. *See* Endoscopy, gastrointestinal; *specific procedures.*
opioid effects on, 781
strictures of, steroid injection for, endoscopic ultrasonography with, 1307

Gastropathy, portal, esophagogastroduodenoscopy in, 1189

Gastroscopy, in peptic ulcer, 1455

Gastrostomy
endoscopic sonographic-guided, 1308
laparoscopic, 1413

GATA-3 transcription factor, inhibitors of, for asthma, 1141–1142

Gay bowel syndrome, sigmoidoscopy in, 1220

Gene therapy, for asthma, 1146–1147

General paresis, in syphilis, 470

Genetic factors
in asthma, **937–950**
in atopy, 940–945
in beta-receptor function, 992–993
in colorectal cancer, **1467–1495**
in dementia, **591–614**
Alzheimer's, 582–583, 591–597, 615–627, 630–637
frontotemporal, 511–512, 601–604
in Huntington's disease, 599–601
in mitochondrial disorders, 608
in prion diseases, 555–556, 604–607
vascular, 598–599
with Lewy bodies, 597
in inflammatory bowel disease, 1497–1498
in irritable bowel syndrome, 1534–1535
in Parkinson's disease, 603

Genitourinary system, opioid effects on, 782

Geriatric evaluation and management units (GEMUs), in outcomes evaluation, 725–726

Geriatric hospital medicine. *See* Elderly persons, hospital medicine for.

Gerstmann-Sträussler-Scheinker disease, 551–552, 605–607

Giardiasis, esophagogastroduodenoscopy in, 1197

Ginger, drug interactions with, 158

Ginkgo biloba
efficacy of, 151, 153–154
for Alzheimer's disease, 665–666
perioperative care and, 801

Ginseng
efficacy of, 151–153
perioperative care and, 801

Glandular tularemia, 399

Glucocorticoid receptors
defects of, in corticosteroid-resistant asthma, 1081–1084
in corticosteroid action, 1079–1081

Gonadotropin-releasing hormone, for irritable bowel syndrome, 1541–1542

Gonorrheal proctitis, sigmoidoscopy in, 1255

Granisetron, for vomiting, in end-of-life care, 763

Granulocyte(s), ehrlichiosis manifestations in. *See* Ehrlichiosis, granulocytotropic.

Granulocyte colony-stimulating factor, for inflammatory bowel disease, 1511–1512

Granulocyte-macrophage colony-stimulating factor, for inflammatory bowel disease, 1511–1512

Granuloma annulare, versus erythema migrans, 253–254

Grief, in end-of-life care, 765

Growth, of infants, massage therapy for, 165–166

Growth hormone, for inflammatory bowel disease, 1512

Guar gum, as herbal medicine, efficacy of, 154–155

Guided imagery, 21–23, 117–118

Guillain-Barré syndrome, versus tick paralysis, 444–445

H

HAART therapy, for AIDS dementia, 544–546

Hahnemann, Samuel, as founder of homeopathy, 47–48

Haloperidol
for delirium, 741, 763

for vomiting, in end-of-life care, 762

Hamartomatous polyposis, of colon, 1486–1487

Hand-assisted laparoscopic surgery, 1419

Handicap, in occupational asthma, 969–970

Hands, laying on of, in spiritual healing, 110–111

Hawthorn, drug interactions with, 158

Headache
biofeedback for, 24
homeopathy for, 58
in babesiosis, 366
in Q fever, 408
in Rocky Mountain spotted fever, 353–354
massage therapy for, 167
relaxation therapy for, 25–26

Health Insurance Portability and Accountability Act of 1996, 880

Heart block, in Lyme disease, 288–290

Heart disorders
in Lyme disease. *See* Carditis, Lyme.
in Q fever, 408–413

Heat
in blood, in Chinese medicine, 67
methods using, for peptic ulcer bleeding, 1322–1325, 1327–1328

Heat therapy, for pain, 792

Heater probe, for colonic bleeding, 1348–1349

Helicobacter pylori infections
endoscopic ultrasonography in, 1293
esophagogastroduodenoscopy in, 1188
peptic ulcer disease and. *See under* Peptic ulcer disease.

Helium-oxygen mixtures, for asthma, 1064

Hemangioma, gastrointestinal
colonoscopy in, 1260
esophagogastroduodenoscopy in, 1191
interventional radiology in, 1367–1374

Hematemesis, esophagogastroduodenoscopy in, 1171

Hematochezia, esophagogastroduodenoscopy in, 1171, 1173

Hematoma, *Arnica* for, 58

Hemobilia, esophagogastroduodenoscopy in, 1192

Hemoclips, for peptic ulcer bleeding, 1328

Hemorrhoids, sigmoidoscopy in, 1254

Hemostasis, colonoscopy in, 1267–1268

Henoch-Schonlein purpura, colonic, colonoscopy in, 1267

Heparin, for venous thromboembolism, postoperative, 743–745

Hepatitis, in Q fever, 407–408, 413

Herbal medicine, **149–161**. *See also specific herbs.*
Ayurvedic, 81–84
Chinese, 72
common products in, 133–137
contaminants of, 158–159
drug interactions with, 156–158
efficacy of, 151–155
flower essences in, 116–117
in naturopathy, 176
perioperative care and, 800–803
quality of, 158–159
regulation of, 158
safety of, 154, 156–159
use of
motivations for, 150
patient characteristics and, 150
prevalence of, 149–150

Hereditary nonpolyposis colorectal cancer, 1474–1479
chemoprevention of, 1478
classification of, 1475–1476
clinical features of, 1474–1475
diagnosis of, 1478
genetic testing in, 1476–1477
historical review of, 1474
natural history of, 1478–1479
surgical approaches to, 1478
surveillance for, 1226–1227, 1477–1478

Hernia
hiatal, esophagogastroduodenoscopy in, 1187
paraesophageal, laparoscopic repair of, 1411

Herpes simplex virus infections
esophageal, esophagogastroduodenoscopy in, 1195–1196
proctitis, sigmoidoscopy in, 1255

Hiatal hernia, esophagogastroduodenoscopy in, 1187

High dilutions, in homeopathy, 51–52

Histamine H_2-receptor antagonists, for gastroesophageal reflux disease, 1427–1428

Holistic care
in Ayurvedic medicine, 77–78
in integrative care, 109
naturopathy in, 175

Home care, for elderly persons, 726–727

Homeopathy, **47–62**
anthroposophic medicine in, 54–55
certification of, 55–56
classic, 54
clinical, 54
combination remedies in, 54
constitutional, 54
history of, 47–48
in naturopathy, 176
interview in, 53–54
outcomes research on, 56–58
pharmacopoeia of, 48
philosophic tenet of, 48–49
practice of, 52–55
clinical, 53–55
remedy selection in, 52–53
scientific tenets of, 49–52
high dilutions effects, 51–52
principle of similars, 49–51
single-remedy preparations in, 54
training for, 55–56

Hope, in end-of-life care, 755

Hormones
at low concentrations, biologic activity of, 50
in irritable bowel syndrome pathogenesis, 1534

Horse chestnut, efficacy of, 152

Hospice care, 766–767

Hospital care, stages of, 693–697
hospital rotation, 693, 695
mandatory hospitalist, 695–697
primary care provider, 693–694
voluntary hospitalist, 693, 695, 697

Hospital medicine
advantages of, 890–891
end-of-life care in, **751–772**, 812–817
ethical issues in, 757–758, **871–888**
evolution of. *See* Hospitalists.
for elderly persons, **709–731**, 802–803
medical errors in, **849–869**, 884–886
models for, ethical issues in, 881–884
pain management, **773–797**
perioperative management, **733–750**, 799–803
program organization for, **889–911**
communication network in, 899–903
fundamental issues in, 889
hospitalist compensation and, 903–906
medical director role in, 906–907
need determination in, 890–891
nighttime coverage in, 898–899
potential benefit determination in, 890–891
practice volume estimation in, 892–894
revenue estimation in, 893
scheduling in, 894–899, 908–911
stakeholder support in, 891–892
quality improvement in, **827–847**
updates on, **799–825**
atrial fibrillation, 818–823
end-of-life care, 812–817
infectious disease, 803–807
perioperative care, 799–803
venous thromboembolism, 807–812

Hospitalists, **689–708**
acceptance of, 691–693
advantages and disadvantages of, 694–696
definition of, 690–691
in rotation, 693, 695
mandatory, 695–697
quality impact of, 697–702
roles of, 702–704
stages of care and, 693, 697
training for, 704–705
voluntary, 693, 695, 697

Host factors, in peptic ulcer disease, 1451–1452

Hot syndrome, in Chinese medicine, 69

House dust mite allergens, environmental controls for, 976–979

Human ehrlichiosis. *See* Ehrlichiosis.

Human immunodeficiency virus infection
anorectal symptoms in, sigmoidoscopy in, 1220
dementia in. *See* AIDS dementia.
esophageal infections in, esophagogastroduodenoscopy in, 1195–1196
massage therapy for, 167–168

Human leukocyte antigens
in asthma, 946–947
in atopy, 944–945

Humidity, control of
for fungal reduction, 985
for house dust mite control, 978–979

Huntington's disease
clinical features of, 599–600
epidemiology of, 600

genetics of, 600–601
pathology of, 600

Hyalomma, host-finding strategies of, 213

Hydrocephalus, normal pressure, dementia in, 471–472

Hydromorphone, for pain, 783

Hydrotherapy, 176

Hydroxychloroquine
for Lyme disease, 347
for Q fever, 412–413

Hydroxyzine, for vomiting, in end-of-life care, 762

Hypercholesterolemia, meditation for, 14, 118–119

Hypersensitivity, visceral, in irritable bowel syndrome, 1529–1530

Hypersensitivity pneumonitis, versus occupational asthma, 965

Hypertension
biofeedback for, 24
meditation in, 118–119
transcendental meditation for, 14

Hypnosis, 18–21
for irritable bowel syndrome, 1543

Hypothyroidism, dementia in, 471

I

Iatrogenic illness, in elderly persons, 718–720

IBD1 gene mutations, in inflammatory bowel disease, 1498

Ileus, postoperative, homeopathy for, 57

Imagery, 21–23, 117–118

Immobility, of elderly persons, in hospital, 713

Immune globulin, intravenous, for asthma, 1086

Immunity, promotion of
imagery for, 117–118
in Ayurvedic medicine, 83–84
massage therapy for, 168–169

Immunofluorescent microscopy, for Rocky Mountain spotted fever, 355

Immunoglobulin E
in asthma, 1093–1094, 1113–1116, 1134–1135
immunotherapy effects on, 1096–1098
inhibitors of, 1135. *See also* Omalizumab.
in atopy, 938, 941–945

Immunoglobulin G, allergen-specific (blocking antibody), in asthma, immunotherapy effects on, 1094–1096

Immunologic occupational asthma, 953–954

Immunomodulators, for inflammatory bowel disease, 1503–1510

Immunotherapy, for asthma, **1091–1112**
accelerated protocols for, 1106
adverse reactions to, 1105–1107
aim of, 1091
allergic response and, 1092–1094
anti-inflammatory cytokines with, 1145
basophil modulation in, 1098
blocking antibody induction in, 1094–1096
contraindications to, 1105
CpG DNA motifs in, 1144–1145
disease progression due to, 1103
DNA vaccines in, 1145
duration of, 1105
efficacy of, 1098–1103
fatal reactions to, 1106
immunoglobulin E decrease in, 1096–1098
immunologic effects of, 1094–1098
lymphocyte subset modulation in, 1098
mast cell modulation in, 1098
modifications of, 1107, 1143–1145
patient selection for, 1104–1105
peptide, 1144
purified vaccines for, 1107
safety equipment for, 1106

Impairment, in occupational asthma, 969–970

Incident reporting, in hospital care, 858–861

Incontinence
fecal, biofeedback for, 24
in elderly persons, in hospital, 721

India, Ayurvedic medicine in. *See* Ayurvedic medicine.

Indinavir, for AIDS dementia, 545

Indirect fluorescent antibody test
for Lyme disease, 327–328
for Rocky Mountain spotted fever, 355

Indirect immunofluorescence test, for *Ehrlichia*, 383

Infants, growth of, massage therapy for, 165–166

Infarction, cerebral, vascular dementia after. *See* Vascular dementia.

Infections
asthma in, 1084
dementia in, 469–470. *See also* AIDS dementia; Prion diseases.
esophageal,
esophagogastroduodenoscopy in, 1195–1196
gastrointestinal
in colonoscopy, 1274–1275
in esophagogastroduodenoscopy, 1201–1202
irritable bowel syndrome in, 1533
nosocomial, in elderly persons, 720
updates on, 803–807

Infectious Disease Society of America, Lyme disease guidelines of, 269–271

Inflammation, airway
beta-agonist effects on, 993
cellular, in asthma, 926
leukotrienes and leukotriene inhibitors and, 1010, 1013

Inflammatory bowel disease, **1497–1523**
adhesion molecule inhibitors for, 1511
aminosalicylates for, 1500–1501
antibiotics for, 1502–1503
colonoscopy in, 1227
colony-stimulating factors for, 1511–1512
corticosteroids for, 1502
cytokine mediators for, 1510–1511
diagnosis of, 1498–1500
endoscopic ultrasonography in, 1303
genetics of, 1497–1498
growth hormone for, 1512
immunomodulators for, 1503–1505
pharmacogenetics of, 1512–1513
sigmoidoscopy in, 1221
tumor necrosis factor inhibitors for, 1505–1510

Infliximab, for inflammatory bowel disease, 1505–1507

Influenza, homeopathy for, 58

Informatics, ethical issues in, 877–881

Informed consent, ethics of, 872–874

Inhalation
of beta-agonists, for asthma, 996–997
of corticosteroids, for asthma. *See* Corticosteroids, for asthma, inhaled.

Injection sclerotherapy, for peptic ulcer bleeding, 1325–1327

Insomnia
relaxation therapy for, 25–26
valerian for, 134

Institute of Medicine, quality health care definition of, 827–828

Insulinoma, endoscopic ultrasonography in, 1301

Integrated pest management, in asthma, 982–983

Integrative care, 109

Integrins, inhibitors, of, for asthma, 1142

Intensive care unit, death in, 767–768

Interferon-α, in asthma, 926–927

Interferon-γ, in asthma, 1132

Interleukin(s)
at low concentrations,
biologic activity of, 50
for inflammatory bowel disease, 1510–1511
in asthma, 1114–1116, 1132
from macrophages, 929–930
from mast cells, 926–927
genetic aspects of, 945–947
immunotherapy effects on, 1098
inhibitors of, 1135–1139
in atopy, genetic aspects of, 941–943

Internet, patient information transmission through, 879–880

Intestinal metaplasia, specialized, in Barrett's esophagus, 1424–1426

Intubation, for asthma, 1065

Intuitive assessments and interventions, 119–120

Intussusception, colonic, colonoscopy in, 1267

Ipratropium bromide, for asthma, 1057, 1059

Iron deficiency anemia, colonoscopy in, 1225–1226

Irritable bowel syndrome, **1525–1551**
clinical features of, 1527–1528
constipation in, 1544–1545
definition of, 1525–1526
diagnosis of, 1535–1537
diarrhea in, 1545
epidemiology of, 1526
outcome of, 1545–1546

painful, treatment of, 1545
pathogenesis of, 1532–1535
pathophysiology of, 1528–1532
sigmoidoscopy in, 1255–1256
societal impact of, 1526
treatment of, 1537–1545
alternative, 1544
constipation-predominant, 1544–1545
diarrhea-predominant, 1545
dietary, 1537–1538
painful, 1545
pharmacologic, 1538–1543
psychologic, 1543

Irritants, in occupational asthma, 954, 959

Ischemia
cerebral, vascular dementia in. *See* Vascular dementia.
in colitis, 1261–1262, 1384–1385
mesenteric, 1377–1390

ISIS-2302 (adhesion molecule inhibitor), for inflammatory bowel disease, 1511

Islet cell tumors, laparoscopic enucleation of, 1417

Isocyanates, asthma induced by, 954, 958–959

Isoproterenol, for asthma, safety of, 995–996

Ixodes dammini. See Ixodes scapularis.

Ixodes holocyclus, tick paralysis caused by, 442–443

Ixodes ricinus, in disease transmission, ehrlichiosis, 377

Ixodes scapularis (deer tick)
attachment of
duration of, 222, 227
sites of, 223
bites of, antibiotics for, 227–228
control of, 223–226
distribution of, 214
feeding of, 214–215
in disease transmission, 221–223
babesiosis, 361, 364–365, 367
ehrlichiosis, 377
Lyme disease. *See* Lyme disease.
life cycle of, 213
morphology of, 222, 245
natural history of, 263–364
nymph form of, morphology of, 245
removal of, 227
water balance of, 209

Ixodidae (hard-bodied ticks). *See also specific tick genera.*
development of, 211
feeding of, 209–211, 214, 222
habitats of, 220–221
life cycles of, 213–215
morphology of, 208–209, 222
taxonomy of, 206
tick paralysis related to, 441–443

J

Jarisch-Herxheimer reaction
after Lyme disease treatment, 251, 256–257
after relapsing fever treatment, 429–430

Jaundice, obstructive, laparoscopic exploration of, 1406–1408

Jehovah's Witnesses, ethical issues related to, 876–877

Joint(s)
Lyme disease affecting. *See* Arthritis, Lyme.
manipulation of. *See* Manual and manipulation techniques.

Joint Commission for Accreditation of Healthcare Organizations, error reporting system of, 859–860

Juvenile polyposis syndrome, 1263, 1486–1487

K

Kapha, in Ayurvedic medicine, 77

Kaposi's sarcoma
colonoscopy in, 1261
esophagogastroduodenoscopy in, 1192

Kava, 136–137, 151–152
perioperative care and, 801

Keliximab, for asthma, 1143

Ketorolac, for pain, 787

Kidney, Chinese herbs effects on, 159

Kinesiology, applied, 113–114

Klüver-Bucy syndrome, 505

Korsakoff's syndrome, 464, 470

Kuru, 551–554, 605

L

Laboratory tests, in operative evaluation, 735

Lactulose, in end-of-life care, 761

Lacunes, in dementia, 484

Lamivudine, for AIDS dementia, 545

Laparoscopic surgery, gastrointestinal, **1401–1422**
anesthesia for, 1401–1402
appendectomy, 1415–1416
cholecystectomy, 1402–1406
colon resection, 1417
common bile duct exploration, 1406–1408
endoluminal, 1419
ergonomics of, 1418–1419
esophageal, 1408–1412
fundoplication, 1410–1411
gastric, 1412–1414
hand-assisted, 1419
injuries during, 1402
liver, 1408
new trends and procedures in, 1418–1419
pancreatic, 1417
paraesophageal hernia repair, 1411
pneumoperitoneum for, 1402
principles of, 1401–1402
robotic, 1419
small intestinal, 1414–1415

Laser therapy, for peptic ulcer bleeding, 1323–1324

Laxatives
for irritable bowel syndrome, 1538
in end-of-life care, 761

LDP-02 (adhesion molecule inhibitor), for inflammatory bowel disease, 1511

Lee Risk Index, for cardiovascular assessment, 736–737

Legal issues
in complementary medicine, **185–196**
malpractice, 191–195
professional licensure, 120, 177–179, 186–189
scope of practice, 190–191
in end-of-life care, 757–758

Leiomyoma, colonic, bleeding from, interventional radiology in, 1371

Leukemia, prayer for, 37

Leukocyte function-associated antigen type-1, inhibitors of, for asthma, 1142

Leukoencephalopathy, in CADASIL, 485, 598–599

Leukopenia
in Colorado tick fever, 437–438
in ehrlichiosis, 382–383

Leukotriene modifiers, for asthma, **1009–1033**
acute, 1027–1028
acute severe, 1061
adverse effects of, 1028
airway inflammation effects of, 1010, 1013
airway remodeling effects of, 1013–1014
antihistamines with, 1023–1024
aspirin-sensitive, 1025–1027
bronchoconstriction effects of, 1014–1016
corticosteroids with, 1020–1021
development of, 1010
exercise-induced, 1024–1025
guidelines for, 1016–1018
mild, 1018–1022
moderate to severe, 1022–1023
pathogenic relationships in, 1009–1012
refractory, 1086–1087
versus inhaled corticosteroids, 1040–1041

Leuprolide, for irritable bowel syndrome, 1541–1542

Levalbuterol, for asthma, 997, 999–1000, 1056

Lewy body disease. *See* Dementia(s), with Lewy bodies.

Liability, in complementary medicine, 194–195

Licensure, in complementary medicine, 120, 177–179, 186–189

Licorice, drug interactions with, 157

Lidamine, for irritable bowel syndrome, 1543

Lidocaine, for pain, 789

Life expectancy, prayer and, 36

Lifestyle counseling, in naturopathy, 176–177

Ligation, of esophageal varices, 1341–1343

Lipoma, colonic, colonoscopy in, 1263–1264

Liver
disorders of, S-adenosyl-L-methionine for, 138
laparoscopic surgery of, 1408

London mutations, in Alzheimer's disease, 631–634

Lone Star tick. *See Amblyomma americanum.*

Loperamide, for irritable bowel syndrome, 1538

Lopinavir, for AIDS dementia, 545

Loratadine, for asthma, leukotriene modifiers with, 1024

Louse, body, relapsing fever transmitted by. *See* Relapsing fever, tick-borne or louse-borne.

Lung cancer, metastatic to mediastinal lymph nodes, endoscopic ultrasonography in, 1301–1302

Lyme disease
- animal models for, 274–275, 287
- arthritis in. *See* Arthritis, Lyme.
- asymptomatic, 273, 342–343
- carditis in. *See* Carditis, Lyme.
- chronic, **341–349**
  - clinical features of, 341–342
  - diagnosis of, 342–345
  - differential diagnosis of, 343–344
  - laboratory testing for, 343–345
  - neurologic involvement in, 279–280
  - pathogenesis of, 342
  - treatment of, 345–347
  - versus late Lyme disease, 343–344
- clinical manifestations of, 264–265, 314–316
  - carditis, 287–291
  - chronic, 341–342
  - erythema migrans, 243–250
  - neurologic, 265–266
- coinfections with, 242, 276–279, 315–316, 382
- diagnosis of, 267–269
  - after vaccination, 232–233
  - chronic, 342–345
  - erythema migrans, 250–251
- differential diagnosis of, 251–254
- early disseminated, 239, 264
- early localized, 264. *See also* Erythema migrans.
- epidemiology of, 242–243, 261–262, 285–286, 314–316
- erythema migrans in. *See* Erythema migrans.
- flu-like illness in, 249–250
- heart involvement in. *See* Carditis, Lyme.
- histology of, 317
- historical perspective of, 240
- in pediatric patients, neurologic involvement, 276
- in pregnancy, 256, 275–276
- laboratory testing for, **311–340**
  - antigen detection assays in, 319–320
  - *Borrelia burgdorferi* biology and, 312–313
  - cautions with, 315
  - chronic, 343–345
  - clinical considerations in, 314–316
  - cultivation in, 316–317
  - direct detection methods for, 316–320
  - epidemiologic considerations in, 314–316
  - histologic, 317
  - immune response assays in, 320–333
    - after vaccination, 332–333
    - cutoff levels for, 321–322
    - enzyme-linked immunosorbent assay, 267, 325–327, 344
    - false-negative reactions in, 323–325
    - false-positive reactions in, 325
    - functional antibody assays, 330–331
    - general considerations in, 321–323
    - indirect fluorescent antibody assay, 327–328
    - lymphoproliferative assays, 332
    - of cerebrospinal fluid, 331–332
    - pretest probability and, 322–323
    - results significance in, 321
    - sensitivity and specificity of, 321
    - two-test approach to, 322
    - Western blot, 267, 328–330, 344–345
  - in carditis, 291–292
  - in erythema migrans, 250
  - in neurologic involvement, 267–269
  - indications for, 311–312
  - polymerase chain reaction in, 317–319
  - urine test for, 318
- late, 264
  - versus chronic Lyme disease, 343–344
- neurologic aspects of. *See* Neurologic disorders, in Lyme disease.
- organ involvement in, 264–265
- pathogen causing. *See* *Borrelia burgdorferi.*
- pathogenesis of
  - chronic, 342

Lyme disease (*continued*)
erythema migrans, 240–242
neurologic involvement, 273–275
pathology of, 286–287
prevention of, 271–272
bite management in, 226–228, 271
bite prevention in, 224–226
vaccine in. *See* Vaccine, for Lyme disease.
rash in. *See* Erythema migrans.
risk factors for, 225–226
seronegative, 267, 323–324
stages of, 264, 285, 314
transmission of, 241, 263–264, 312–313
by nymphal ticks, 222
duration of tick attachment and, 222, 226–227
with other tick-borne diseases, 223
treatment of
arthritis, 298, 305–307
chronic, 345–347
erythema migrans, 255–257
historical perspective of, 240
neurologic, 269–271
outcome of, 257–258
with diagnostic uncertainty, 254–255
vectors for, 241–243, 263–264, 285–286, 312–313

Lymph nodes, mediastinal, metastasis to, endoscopic ultrasonography of, 1302

Lymphadenopathy, in tularemia, 399

Lymphatic massage, for edema, 98

Lymphocytes, in asthma, 929. *See also* T lymphocytes, in asthma.

Lymphocytic colitis, colonoscopy in, 1259

Lymphocytic meningoradiculitis, in Lyme disease, 266

Lymphoma
colonic, colonoscopy in, 1265
gastric, esophagogastroduodenoscopy in, 1200–1201
MALT, endoscopic ultrasonography in, 1297

Lymphopenia, in Colorado tick fever, 437–438

Lymphoproliferative assays, for Lyme disease, 332

Lynch syndrome (hereditary nonpolyposis colorectal cancer), 1226–1227, 1474–1479

M

Ma Huang, perioperative care and, 801

Macrophages, in asthma, 929–930

Mad cow disease. *See* Creutzfeldt-Jakob disease, variant.

Madhav Nidan (MN), in Ayurvedic medicine, 76, 78–79

Magnesium sulfate, for asthma, 1060–1061

Magnetic gait, in normal pressure hydrocephalus, 471

Magnetic resonance imaging
in dementia, 460, 542–543
in mesenteric ischemia, 1387

Maharishi Mahesh Yogi method, of transcendental meditation, 13–15

Malabsorption
esophagogastroduodenoscopy in, 1177–1178, 1196–1198
irritable bowel syndrome in, 1533–1534

Mallory-Weiss tears
angiography for, 1362
endoscopic diagnosis and therapy of, 1189, 1333–1334

Malnutrition, in elderly persons, in hospital, 722

Malpractice, in complementary medicine, 191–195

MALT lymphoma, endoscopic ultrasonography in, 1297

Manual and manipulation techniques
for rheumatic disease, **91–103**
back pain, 94–95
categories of, 92
chiropractic, 91, 99–100
definition of, 92
massage therapy, 97–98
mechanisms of action of, 92–94
osteopathic, 98–99
safety of, 97
in naturopathy, 176

MAP kinases, inhibitors of, for asthma, 1141

Massage therapy, 97–98, **163–171**
advantages of, 164
for anorexia nervosa, 166
for asthma, 169
for autoimmune conditions, 169
for breast cancer, 168–169
for depression, 166
for diabetes mellitus, 169–170

for fibromyalgia, 167
for HIV infection, 167–168
for immune disorders, 167–169
for infant growth, 165–166
for migraine headache, 167
for smoking cessation, 166
historical background of, 163
types of, 164–165

Mast cells, in asthma, 926–927, 1116
beta-agonist effects on, 993
immunotherapy effects on, 1098

Material safety data sheets, for occupational exposures, 961

Mebeverine, for irritable bowel syndrome, 1539–1540

Mechanical ventilation
for asthma, 1065
for chronic obstructive pulmonary disease exacerbations, 817
postoperative, 743
withdrawal of, in end-of-life care, 768

Meckel's diverticulum
laparoscopic resection of, 1415
nuclear bleeding scan in, 1375–1376

Meclizine, for vomiting, in end-of-life care, 762

Medical director, of hospital medicine program, 906–907

Medical errors, in hospital medicine, **849–869**
acts of omission, 853
analysis of, 861–863
definition of, 853–854
epidemiology of, 850–853
ethical issues in, 884–886
evidence-based safety practices developed from, 863–865
in attentional behavior, 854–855
in schematic behavior, 854–855
incident reporting of, 858–861
latent, 862–863
mistakes, 856
nonmedical systems applied to, 858–859
psychology of, 853–858
reduction of, recommendations for, 857–858
reporting and responding to, 857–863
responses to, 856–857
slips, 856
types of, 856
unanticipated nature of, 853–854
versus adverse events, 851, 853

Medical history, in preoperative evaluation, 734–735

Meditation, 12–18
concentration response, 15–16
mindfulness, 16–18
transcendental, 13–15
types of, 12–13
versus prayer, efficacy of, 38

Melanosis coli, colonoscopy in, 1265

Melena, esophagogastroduodenoscopy in, 1171

Memantine, for vascular dementia, 490

Memory deficits
in dementia, 456–457
in Huntington's disease, 599
versus dementia, 464

Menetrier's disease
endoscopic ultrasonography in, 1293
esophagogastroduodenoscopy in, 1199–1200

Meningitis, in Lyme disease, 266, 276

Mental status examination, in dementia, 458–460

Meperidine, for pain, 785

6-Mercaptopurine, for inflammatory bowel disease, 1503–1504, 1512–1513

Meridians, 64, 113–115

Mesalamine, for inflammatory bowel disease, 1501

Mesenteric angiography, versus colonoscopy, 1276

Mesenteric ischemia
interventional radiology in, 1377–1390
acute
in arterial disease, 1377–1383
in colitis, 1384–1386
in venous thrombosis, 1383–1384
chronic, in colitis, 1386–1390
nonocclusive, 1380, 1382

Metabolic disorders, dementia related to, 470–471

Metabolism, beta-agonist effects on, 994

Metaproterenol, for asthma, 997–998, 1000

Metered dose inhalers, for beta-agonist delivery, in asthma, 996

Methacholine challenge testing, in occupational asthma, 963–964

Methadone, for pain, 785–786

Methotrexate
for asthma, 1085–1086
for inflammatory bowel disease, 1504

Methylphenidate, in end-of-life care, 760–761, 763

Methylprednisolone, for asthma, 1058

Methylxanthines, for asthma, 1062–1063

Metronidazole
for *Helicobacter pylori* infection, 1459–1460
for inflammatory bowel disease, 1502–1503

Microflora, gastrointestinal, in irritable bowel syndrome, 1532–1533

Microimmunofluorescence test, for *Coxiella burnetii*, 410–411

Microsatellite instability, in colorectal cancer, 1471–1472

Microscopic examination, of tissue, in Lyme disease diagnosis, 317

Microtubule-associated proteins, Tau as. *See tau* gene and protein.

Migraine
homeopathy for, 58
massage therapy for, 167

Mind-body medicine, **11–31**
biofeedback in, 23–25
combination therapies in, 26
guided imagery in, 21–23, 117–118
history of, 11–12
hypnosis in, 18–21
meditation in, 12–18, 118–119
concentration response, 15–16
mindfulness, 16–18
transcendental, 13–15
types of, 12–13
relaxation therapy in, 15–16, 19, 25–26

Mindfulness meditation, 16–18

Minerals, supplementary, 132–133

Mini-Mental State Examination, in dementia, 459

Minors, informed consent for, 874

Misoprostol, for peptic ulcer disease, 1453–1454

Mite allergens, environmental controls for, 976–979

Mitochondrial disorders, dementia in, 608

MLH protein, in hereditary nonpolyposis colorectal cancer, 1476–1477

Mold allergens, environmental controls for, 983–986

Monoclonal antibodies, for asthma, 1143. *See also* Omalizumab.

Monocytes, ehrlichiosis manifestations in. *See* Ehrlichiosis, monocytotropic.

Montelukast, for asthma
acute, 1028, 1061
adverse effects of, 1028
airway remodeling and, 1013
antihistamines with, 1024
aspirin-sensitive, 1027
availability of, 1010
bronchodilating effects of, 1015–1016
exercise-induced, 1025
mild, 1018–1021
refractory, 1086–1087
severe, 1022–1023, 1061
versus inhaled corticosteroids, 1040–1041

Morphine
for pain, 782–783
in end-of-life care, 759–761

Mortality, from hospital errors, 849

Motility disorders
gastrointestinal, esophagogastroduodenoscopy in, 1194–1195
in irritable bowel syndrome, 1528–1529

Motor neuron disease, frontotemporal dementia with, 507

Motor symptoms, in dementia
AIDS, 539
with Lewy bodies, 524–525, 528

Mountain fever and mountain tick fever. *See* Colorado tick fever.

MSH protein, in hereditary nonpolyposis colorectal cancer, 1476–1477

MSI protein, in hereditary nonpolyposis colorectal cancer, 1476, 1479

Mucociliary clearance, beta-agonist effects on, 993

Mucolytics, for asthma, 1063

Multidisciplinary team, for quality improvement, 839–840

Muscle(s)
beta-agonist effects on, 994

manipulation of. *See* Manual and manipulation techniques.
opioid effects on, 782

Myalgia
in Colorado tick fever, 437
in Q fever, 408

Myocardial infarction
colonoscopy in, 1229–1230
esophagogastroduodenoscopy in, 1180
postoperative, 741–742

Myocarditis, in Lyme disease, 290–291

N

Naloxone, for opioid reversal, 786

Narcotics. *See* Opioids.

Naturopathy, **173–184**
definition of, 173
efficacy of, 180–181
future of, 181–182
history of, 173–174
modalities in, 176–177. *See also specific modalities.*
practice of, 176–177
principles of, 174–176
safety of, 180–181
training for, 177–180

Nausea and vomiting
esophagogastroduodenoscopy in, 1174–1175
in end-of-life care, 762–763
opioid-induced, 781

Nebulizers, for beta-agonist delivery, in asthma, 997, 1056

Neck pain
chiropractic care for, 99–100
manipulation techniques for, 93–95

Nelfinavir, for AIDS dementia, 545

Nephropathy, Chinese herbs, 159

Network chiropractic care, 111–113

Neuritic plaques, in Alzheimer's disease, 591–592, 629, 632–633. *See also* Beta-amyloid.

Neuroendocrine tumors, of pancreas, endoscopic ultrasonography in, 1300–1301

Neurofibrillary tangles, in Alzheimer's disease, 591–592, 629. *See also tau* gene and protein, defects of.

Neurohumoral disturbances, in irritable bowel syndrome, 1534

Neuroimaging, in dementia, 460–461

Neuroleptics, for delirium, in elderly persons, 716–717

Neurologic disorders
in Colorado tick fever, 437
in Lyme disease
cerebrospinal fluid analysis in, 331–332
chronic, 279–280, 342
coinfections with, 276–279
diagnosis of, 267–269
in pediatric patients, 276
in pregnancy, 275–276
pathogenesis of, 273–275
treatment of, 269–271
types of, 265–266
in Q fever, 408
in Rocky Mountain spotted fever, 354, 356
tick paralysis as, **441–446**

Neuropathic pain, 775

Neurosyphilis, dementia in, 470

Neutropenia, in Colorado tick fever, 437–438

Neutrophils, in asthma, 928–929

Nevirapine, for AIDS dementia, 545–546

Nicardipine, for vascular dementia, 490

Nicergoline, for vascular dementia, 490

Nimodipine, for vascular dementia, 490

Nissen fundoplication, laparoscopic, 1410–1411

Nociceptors, 774

Nocturnal asthma, beta-agonists for, 1003–1004

NOD2 gene mutations, in inflammatory bowel disease, 1497–1498

Nonsteroidal anti-inflammatory drugs
for pain, 786–787
in end-of-life care, 759
management of, in esophagogastroduodenoscopy, 1170
peptic ulcer disease due to, 1452–1454

Nosocomial infections, in elderly persons, 720

notch3 gene, mutations of, in vascular dementia, 485, 598–599

Nuclear bleeding scans
in colonic varices and

Nuclear bleeding scans (*continued*)
hemangiomas, 1367–1370
in small intestinal bleeding, 1345–1346, 1375–1376

Nuclear factor-κB, in asthma
corticosteroid-resistant, 1083–1084
inhibitors of, 1142

Numeric rating scales, for pain assessment, 777–778

Nutrition
for elderly persons, in hospital, 722
in end-of-life care, 764
with dementia, 814
withdrawal of, 758

Nutritional supplements. *See* Dietary supplements; Herbal medicine.

Nuttalliella, 206

Nymphs, tick. *See* Tick(s), nymph form of.

O

Obesity, Ayurvedic medicine for, 85

Obstructive defecation, biofeedback for, 24

Obstructive sleep apnea, postoperative complications of, 802

Occupational asthma, **951–971**
causes of, 955–959
challenge testing in, 963–964
compensation in, 969–970
definition of, 951–952
diagnosis of, 959–965
differential diagnosis of, 965–967
disability in, 969–970
epidemiology of, 952–953
healthy worker effect in, 952
history in, 961–962
immunologic, 953–954
impairment in, 969–970
irritant-induced, 954, 958
multiple mechanisms in, 954, 957
pathogenesis of, 953–957
prevention of, 968
prognosis for, 968–969
pulmonary function testing in, 963
radiography in, 961, 963
risk factors for, 957–958
skin testing in, 964
treatment of, 967–968
versus nonoccupational asthma, 965–967
versus other occupational lung diseases, 965–967
worksite evaluation in, 965

Occupational bronchitis, 966

Octreotide, for varices, 1338

Oculoglandular tularemia, 399

Odynophagia,
esophagogastroduodenoscopy in, 1194–1196

Ogilvie's syndrome, colonoscopy in, 1268–1269

Ohara's disease. *See* Tularemia.

Ojas, in Ayurvedic medicine, 77–78

Omalizumab, for asthma, 1087
aerosolized delivery of, 1119
clinical trials of, 1119–1126
dosage for, 1120–1121
efficacy of, 1119–1126, 1135
mechanism of action of, 1116–1118, 1135
pharmacokinetics of, 1118–1119
side effects of, 1124

Omega-3 fatty acids, as dietary supplements, 139–140

Omeprazole, for peptic ulcer disease, 1453–1454

OmpC antigen, in inflammatory bowel disease, 1499

Ondansetron
for irritable bowel syndrome, 1540–1541
for vomiting, in end-of-life care, 763

Opioids
equivalent dosing chart for, 794
for dyspnea, in end-of-life care, 762
for pain
adverse effects of, 781–782
classification of, 780
concerns about, 790–791
"double effect," 758
in end-of-life care, 758–761
in World Health Organization analgesic ladder, 790
individual agents, 782–786
receptors for, 780
reversal of, 786
types of, 794

Ornithodoros
biology of, 420–423
life cycle of, 212–213
relapsing fever transmitted by, 418, 420–423

Oropharyngeal tularemia, 399–400

Orthoses, for proprioception improvement, 96

Osteoarthritis
S-adenosyl-L-methionine for, 138
manipulation techniques for, 94–97

Osteopathy, 98–99
craniosacral, 111–113

Osteoporosis, in inhaled corticosteroid therapy, 1043

Otitis media, homeopathy for, 57–58

Outcomes, of hospital care
measures of, in quality improvement, 830–831, 837–838
of elderly persons, 725–726

Oxidative stress, in prion diseases, 565–567

Oxiracetam, for vascular dementia, 490

Oxycarbazepine, for pain, 789

Oxycodone, for pain, 783–784

Oxygen therapy
for asthma, 1054–1055, 1059, 1064
for dyspnea, in end-of-life care, 762

p53 gene, mutations of, in colorectal cancer, 1470–1471

P

Pacemaker, for Lyme carditis, 292–293

Pain, **773–797**
abdominal
esophagogastroduodenoscopy in, 1175
in irritable bowel syndrome, 1527, 1545
assessment of, 776–778
epigastric,
esophagogastroduodenoscopy in, 1192–1194
factors affecting, 775–776
fear of, 773
management of
guided imagery for, 22, 117–118
hypnosis for, 20
improvements in, 792–793
in end-of-life care, 758–761
manual techniques for. *See* Manual and manipulation techniques.
meditation for, 17–18, 118–119
nonopioid analgesics for, 786–789
nonpharmacologic, 791–792
opioids in. *See* Opioids.
pharmacokinetic considerations in, 778–780
World Health Organization three-step analgesic ladder for, 789–790
neuropathic, 775
pathophysiology of, 774
somatic, 775
types of, 774–775
visceral, 775

Palliative care. *See* End-of-life care.

Panchbootas, in Ayurvedic medicine, 8, 76

Panchkarma, in Ayurvedic medicine, 81

Pancreas
endoscopic ultrasonography of
in cancer, 1299–1301
in cystic neoplasms, 1302
in neuroendocrine tumors, 1300–1301
in pancreatitis, 1298
laparoscopic surgery on, 1417
pseudocysts of, endoscopic sonographic-guided drainage of, 1307–1308

Pancreatitis
endoscopic ultrasonography in, 1298
in common bile duct obstruction, laparoscopic exploration of, 1406–1408

Panendoscopy, in gastrointestinal bleeding, 1359

Papaverine, for mesenteric ischemia, in arterial disease, 1381–1383

Paraesophageal hernia, laparoscopic repair of, 1411

Paralysis, tick. *See* Tick paralysis.

Parkinson's disease
dementia with, 467–469
dementia with Lewy bodies and, 467–469, 519–521, 524–525
frontotemporal dementia with, 511
genetics of, 603

Patients' Bill of Rights, 879

Pediatric patients
biofeedback in, 24–25
colonoscopy in, 1238–1239
diarrhea in, homeopathy for, 57
growth of, massage therapy for, 165–166
Lyme disease in, 276

Peglyation, of cytokines, for asthma, 1146

Pelvic floor dyssynergia, biofeedback for, 24

Penicillin(s), for Lyme disease, 256, 270

Penicillin G, for relapsing fever, 429

Penicillium allergens, environmental controls for, 984–986

Pentoxifylline, for vascular dementia, 491

Peppermint oil, for irritable bowel syndrome, 1539

Peptic ulcer disease, **1447–1466**
anastomotic, 1191
bleeding in, 1455, 1460
angiography for, 1361
endoscopic therapies for
active arterial, 1328
electrocoagulation, 1324–1325
heater probe, 1325, 1329
ideal features of, 1322
oozing, 1330–1331
retreatment in, 1332
safety of, 1332
sclerotherapy, 1325–1327
second-look, 1332
thermally active methods, 1322–1325, 1327–1328
with flat spots, 1331–1332
with nonbleeding adherent clot, 1321, 1329–1330
with nonbleeding visible vessel, 1321, 1329
stigmata of, 1320–1322
clinical manifestations of, 1455
complications of, 1460
diagnosis of, 1455–1458
diseases associated with, 1458
epidemiology of, 1447–1448
esophagogastroduodenoscopy in, 1178–1179, 1193–1194
Helicobacter pylori and
diagnosis of, 1455–1458
epidemiology of, 1447–1448, 1452
pathogenesis of, 1448–1452
treatment of, 1458–1460
pathogenesis of, 1448–1454
Helicobacter pylori in, 1448–1452
NSAIDs in, 1452–1454
perforation of, laparoscopic plication of, 1413
stress and, 1454–1455
treatment of, 1458–1461

Peptide immunotherapy, for asthma, 1144

Perforation, in peptic ulcer disease, 1460

Perioperative management, **733–750**
consultation in, 733–734
herbal medicines and, 800–802
of anticoagulation, 743–746
of postoperative complications, 738–744
age considerations in, 802–803
delirium, 739–741
myocardial infarction, 741–742
pulmonary, 742–743
sleep apnea, 802
venous thromboembolism, 743–744
preoperative evaluation in, 734–738
cardiovascular risk assessment in, 735–737, 799–800
history in, 734–735
laboratory tests in, 734–735
physical examination in, 734–735
pulmonary risk assessment in, 737–738
updates on, 799–803

Permethrin, for tick control, 226

Pernicious anemia, atrophic gastritis in, esophagogastroduodenoscopy in, 1177

Pesticides, in cockroach extermination, 982–983

Pet allergens, environmental controls for, 979–981

Petrissage, 97, 164

Peutz-Jeghers syndrome, 1486

Pharmacodynamics, nonlinear, 51

Pharmacokinetics, of pain medications, 778–780

Pharyngitis, in tularemia, 399–400

Phenytoin, for pain, 788

Phlebectasia, colonoscopy in, 1261

Phosphodiesterase, inhibitors of, for asthma, 1139–1140

Photodynamic therapy, for Barrett's esophagus, 1437–1438

Physical examination, in preoperative evaluation, 734–735

Physician-patient relationship
in hospitalist model, 881–882
informatics and, 881

Pick complex, versus Pick's disease, 509–510

Picker/Commonwealth Program, in quality improvement, 833–834

Pick's disease, 502–504, 601

Piracetam, for vascular dementia, 490

Pirbuterol, for asthma, 997–998, 1000

Pitta, in Ayurvedic medicine, 77

Pityriasis rosea, versus erythema migrans, 253–254

Placebo effects, in energy medicine, 108

Plan-Do-Check-Act cycles, in quality improvement, 832–833

Plant allergens, occupational asthma induced by, 958–959

Pleural effusions, malignant, chest tubes for, 814–815

Plummer-Vinson syndrome, esophagogastroduodenoscopy in, 1195

Pneumatosis coli, colonoscopy in, 1266

Pneumococcal bacteremia, treatment of, 803–805

Pneumonia
in Q fever, 407–408, 412
in tularemia, 400–401
postoperative, 742–743

Pneumonitis, hypersensitivity, versus occupational asthma, 965

Pneumoperitoneum, for laparoscopic surgery, 1402

Pobilukast, for asthma, airway remodeling and, 1013

Poliomyelitis, versus tick paralysis, 444

Polychrests, in homeopathy, 54

Polyethylene glycol moieties, attached to therapeutic proteins, for asthma, 1146

Polyethylene glycol solution, for bowel preparation, 1234

Polymerase chain reaction
for *Borrelia*, 317–319
for *Ehrlichia*, 384
for *Francisella tularensis*, 402
reverse-transcriptase, for Colorado tick fever virus, 438

Polyp(s)
colonic, colonoscopy in, 1262–1264, 1269–1270
gastric, esophagogastroduodenoscopy in, 1198–1199

Polypectomy, colonic, 1269–1270
anticoagulation in, 1233
complications of, 1271, 1273–1274
new developments in, 1279

Polyposis
familial adenomatous, 1479–1485
hamartomatous, 1486–1487

Porifimer sodium, in photodynamic therapy, for Barrett's esophagus, 1437

Portal colopathy, colonoscopy in, 1262

Portal gastropathy, esophagogastroduodenoscopy in, 1189

Positive pressure ventilation, noninvasive, for asthma, 1065

Postoperative complications, 738–744
age considerations in, 802–803
delirium, 739–741
myocardial infarction, 741–742
pulmonary, 742–743
sleep apnea, 802
venous thromboembolism, 743–744

Posttraumatic stress disorder, eye movement desensitization and reprocessing technique for, 115–116

Postural instability, in dementia with Lewy bodies, 524–525

Practice, scope of, in complementary medicine, 190–191

Prakruti, in Ayurvedic medicine, 77–79

Pranlukast, for asthma
airway remodeling and, 1013
availability of, 1010
severe, 1022

Prayer, in health care, **33–46**, 110–111
belief in, 33–34
benefits of, 35–41
frequency of, 40
history of, 33
intercessory, 37–38
potency of, 41
quality of, 41–42
study design for, 41–43
use statistics for, 33–35

Prednisolone, for asthma, 1058

Prednisone
for asthma, 1058
for Q fever, 413

Pregnancy
colonoscopy in, 1228–1229
esophagogastroduodenoscopy in, 1180–1181
Lyme disease in, 256, 275–276
Q fever in, 405, 410
tick-borne relapsing fever in, 424

Premalignant lesions, gastrointestinal, esophagogastroduodenoscopy in, 1198–1200

Preoperative evaluation, 734–738
cardiovascular risk assessment in, 735–737, 799–800
history in, 734–735
laboratory tests in, 735
physical examination in, 734–735
pulmonary risk assessment in, 737–738

Presenilin defects, in Alzheimer's disease, 594–596, 632, 634–635

Pressure ulcers, in elderly persons, in hospital, 721–722

Primary progressive aphasia, 507–508

Principle of similars, in homeopathy, 49–51

Prion diseases, **551–571**
agents causing, 555–557
classification of, 551–552
clinical features of, 553–554
diagnosis of, 567–568
epidemiology of, 553
genetics of, 604–607
histopathology of, 551, 563
historical background of, 552–553
iatrogenic, 554
molecular typing of, 564–565
pathogenesis of, 557–562, 565–567
prognosis for, 553–554
surveillance of, 567–568
transmission of, 552–555, 563–564
types of, 551
variant Creutzfeldt-Jakob situation, 562–564

Privacy, concerning health data, 877–881

Probe, heater
for colonic bleeding, 1348–1349
for peptic ulcer bleeding, 1325, 1329

Prochlorperazine, for vomiting, in end-of-life care, 762

Proctitis, sigmoidoscopy in, 1255

Proctocolectomy
for familial adenomatous polyposis, 1483
laparoscopic, 1417

Professional licensure, in complementary medicine, 120, 177–179, 186–189

Professionalism, in hospital medicine, 885–886

Progressive relaxation training, 25–26

Progressive subcortical gliosis, versus Pick's disease, 504

Prokinetic agents, for irritable bowel syndrome, 1541

Propoxyphene, for pain, 786

Proprioception exercises, for muscle pain, 96

Protein C, activated, for sepsis, 805–807

Proton pump inhibitors
for gastroesophageal reflux disease, 1427–1428
for peptic ulcer disease, 1459

Provings, in homeopathy, 52

PrPs (prion proteins), 555–568
characteristics of, 555–557
conversion of normal to scrapie type, 557–562
detection of, 567–568
in variant Creutzfeldt-Jakob disease, 562–564
molecular biology of, 564–565
oxidative stress on, 565–567
protein kinase-resistant, 558–560

Pseudomembranous colitis, colonoscopy in, 1257

Psychiatric disorders
in dementia
AIDS, 539
in Huntington's disease, 599
with Lewy bodies, 523–524, 527–528
in irritable bowel syndrome, 1532
mindfulness meditation for, 17–18
prayer for, 35
transcendental meditation for, 14–15

Psychosis, in dementia with Lewy bodies, 527–528

Psychosocial support, in end-of-life care, 765–766

Psychotherapy
applied kinesiology with, 114
for irritable bowel syndrome, 1543
meridian-based techniques in, 115

PTEN gene, mutations of, in juvenile polyposis syndrome, 1487

Pulmonary complications, postoperative, 742–743

Pulmonary embolism, diagnosis of, 807–811

Pulmonary function testing, in asthma
acute severe, 1051, 1054
occupational, 963
refractory, 1078

Pulmonary risk assessment, in preoperative evaluation, 737–738

Pulse evaluation, in Chinese medicine, 69

Pure consciousness, in transcendental meditation, 13–15

Purification, in Ayurvedic medicine, 80–81

Push enteroscopy, in small intestinal bleeding, 1345, 1375

Pyrosis, esophagogastroduodenoscopy in, 1175

Q

Q fever, 404–413
- acute, 407–409
- chronic, 409–410
- clinical manifestations of, 407–410
- diagnosis of, 410–411
- epidemiology of, 405–406
- historical perspectives of, 404–405
- in pregnancy, 405, 410
- laboratory testing for, 410–411
- microbiology of, 406–407
- pathogenesis of, 406–407
- transmission of, 405–406
- treatment of, 411–413
- vectors for, 404–405

Qi (energy) principle, in Chinese medicine, 64, 66–67

Qigong, 110–111

Quality improvement, in hospital care, **827–847**
- active participation in, 841–842
- case study of, 842–844
- competing systems for, 838–839
- definition of, 827–828
- goals of, 828–830
- hospitalists impact on, 697–702
- measurement of, 830–831, 835–838
- models for, 828
- multidisciplinary for, 839–840
- organizational culture and, 840–841
- patient experience and, 833–834
- Plan-Do-Check-Act cycles in, 832–833
- potential changes for, 831–832
- process understanding for, 835
- system for, 828

Quality of care, in hospital, of elderly persons, 722–724

Quinine, for babesiosis, 368–369

R

Rabbit fever. *See* Tularemia.

Radiation colitis, colonoscopy in, 1259

Radiculoneuritis, in Lyme disease, 266

Radiofrequency ablation, endoscopic sonographic-guided, of pancreatic tumors, 1308

Ranitidine, for *Helicobacter pylori* infection, 1459–1460

K-*ras*gene, mutations of, in colorectal cancer, 1469–1470

Rasa, in Ayurvedic medicine, 77

Rasayana, in Ayurvedic medicine, 77–78, 83–84

Rash
- in Colorado tick fever, 437
- in Lyme disease. *See* Erythema migrans.
- in Rocky Mountain spotted fever, 353–354

Raynaud's phenomenon, omega-3 fatty acids for, 139–140

Reactive oxygen species, in prion diseases, 565–567

Rectum
- bleeding from, sigmoidoscopy in, 1221
- cancer of. *See also* Colorectal cancer, endoscopic ultrasonography in, 1303–1304
- condyloma acuminata of, sigmoidoscopy in, 1255
- gonorrhea of, sigmoidoscopy in, 1255
- solitary ulcer of, sigmoidoscopy in, 1254–1255
- varices of, sigmoidoscopy in, 1254

Red cedar dust, asthma induced by, 954

Red clover, drug interactions with, 158

Reduction, in Ayurvedic medicine, 81

Reflexology, 164–165

Reflux, gastroesophageal. *See* Gastroesophageal reflux disease.

Refractory asthma, **1073–1090**
- corticosteroid resistance in, 1079–1084
- definition of, 1073–1074
- diagnosis of, 1074–1078
- differential diagnosis of, 1075–1076
- epidemiology of, 1078
- in viral infections, 1084
- pathology of, 1078–1079
- treatment of, 1084–1087

Regulations, on privacy of information, 880

Reiki, 110–111

Relapsing fever, tick-borne or louse-borne, **417–433**
clinical manifestations of, 417–418, 424–426
differential diagnosis of, 425–426
epidemiology of, 418–420
historical perspective of, 417–418
in pregnancy, 424
laboratory diagnosis of, 426–428
mortality in, 424–425
pathogenesis of, 423–424
pathogens causing, 420
prevention of, 430
transmission of, 420–423
treatment of, 428–430
vectors for, 420–423

Relaxation, 15–16, 19, 25–26

Religiosity. *See* Prayer.

Remission, spontaneous, in energy medicine, 108

Repellents, tick, 226

Repertory, in homeopathy, 52–54

Respirable antisense oligonucleotides, for asthma, 1145–1146

Respiratory complications, of gastrointestinal bleeding, 1320

Respiratory depression, opioid-induced, 781

Respondent superior doctrine, in error reporting, 885

Restraints
ethical issues concerning, 877
for elderly persons, in hospital, 717–718

Resuscitation, orders for, in end-of-life care, 753–754

Retinal pigmented epithelium, congenital hypertrophy of, in familial adenomatous polyposis, 1482

Reverse-transcriptase polymerase chain reaction, for Colorado tick fever virus, 438

Rheumatic disease
Ayurvedic medicine for, 84–85
manual and manipulation techniques for, **91–103**
omega-3 fatty acids for, 139–140

Rhinitis, allergic
asthma with, 1103
homeopathy for, 57

Rickettsia rickettsii infection. *See* Rocky Mountain spotted fever.

Rifampin, for ehrlichiosis, 385

Rigidity, in dementia with Lewy bodies, 524–525

Rings, esophageal, esophagogastroduodenoscopy in, 1195

Ritonavir, for AIDS dementia, 545

Rivastigmine
for Alzheimer's disease, 660–661
for dementia with Lewy bodies, 527–528, 666–667
for vascular dementia, 491–492

Robotic surgery, gastrointestinal, 1419

Rocky Mountain spotted fever, **351–360**
asymptomatic, 353
clinical features of, 353–355
Colorado tick fever with, 437
diagnosis of, 355
epidemiology of, 352–353
laboratory testing for, 354
microbiology of, 351–352
mortality in, 353
pathology of, 354–355
spotless, 354
treatment of, 356–358
vectors for, 352–353

Rofecoxib, for pain, 787

Roflumilast, for asthma, 1140

Root cause analysis, of medical errors, 861–863

Saccharomyces cerevisiae antibodies, in inflammatory bowel disease, 1498–1499

S

Safety practices, for medical error reduction, 863–865

St. John's wort, 135–136, 151–152

Salmeterol, for asthma, 998–999, 1001
exercise-induced, 1025
inhaled corticosteroids with, 1041–1043

SAMe (S-adenosyl-L-methionine), as dietary supplement, 138

Saquinavir, for AIDS dementia, 545

Sarcoma, Kaposi's
colonic, colonoscopy in, 1261
esophagogastroduodenoscopy in, 1192

Scheduling, for hospital medicine program, 894–899, 908–911
call-based, 895–896
hybrid, 896–898
nighttime coverage in, 898–899
samples of, 908–911
shift-based, 895

Scleroderma, motility disorders in, esophagogastroduodenoscopy in, 1194–1195

Sclerotherapy
for esophageal varices, 1338–1341
for peptic ulcer bleeding, 1325–1327

Scope of practice, in complementary medicine, 190–191

Scopolamine, for death rattle management, 764

Scrapie
prion protein in
characteristics of, 555–556
conversion from normal type, 557–562
detection of, 567–568
molecular typing of, 564–565
species barrier penetration by, 553
transmission of, 553, 555
versus human prion diseases, 552

Seattle Protocol, for behavioral disturbance management, 643–644

Sedation
for asthma, 1063
for colonoscopy, 1235–1236
for esophagogastroduodenoscopy, 1182
in Chinese medicine, 67

Selectins, inhibitors of, for asthma, 1142

Selegiline, for AIDS dementia, 547

Selenium, supplementary, 132–133

Semantic dementia, 507–508

Senile dementia of the Binswanger type, 484–485

Senna, in end-of-life care, 761

Senses, in Ayurvedic medicine, 79

Sensitization, in asthma, 1114

Sensory disorders, visceral, in irritable bowel syndrome, 1529–1530

Sepsis, activated protein C for, 805–807

Serotonin, at low concentrations, biologic activity of, 1534

Serotonin receptor antagonists, for irritable bowel syndrome, 1540–1541

Sexual abuse, irritable bowel syndrome in, 647–648

Sick building syndrome, 965, 967

Side effects, in homeopathy, 52

Sigmoidoscopy
flexible, **1217–1252**
colonic preparation for, 1234
complications of, 1231
contraindications for, 1231–1232
findings in, 1254–1256
in anal fissure, 1254
in anorectal varices, 1254
in colitis cystica profunda, 1255
in colorectal cancer screening, 1472
in condyloma acuminata, 1255
in gonorrheal proctitis, 1255
in hemorrhoids, 1254
in herpes simplex proctitis, 1255
in irritable bowel syndrome, 1255–1256
in solitary rectal ulcer, 1254–1255
indications for, 1220–1223
in higher risk patients, 1228–1231
instruments for, 1238–1239
preprocedure evaluation and instructions for, 1232–1234
sedation for, 1235–1236
therapeutic, 1223
versus rigid, 1218, 1220
historical background of, 1217–1219

Signaling molecules, inhibitors of, for asthma, 1141–1142

Simethicone, for irritable bowel syndrome, 1542

Similars, principle of, in homeopathy, 49–51

Skin lesions
in Lyme disease. *See* Erythema migrans.
in tularemia, 399

Skin test reactivity
for occupational asthma, 964
in atopy, 938, 943–944

Sleep apnea, obstructive, postoperative complications of, 802

Sleep disorders
in dementia, 647–648
in irritable bowel syndrome, 1532

Small intestine
aortic fistula with

Small intestine (*continued*)
endoscopic diagnosis and therapy of, 1337
esophagogastroduodenoscopy in, 1192
bleeding in
endoscopic diagnosis and therapy of, 1344–1347
interventional radiology in, 1375–1376
cancer of, endoscopic diagnosis and therapy of, 1336–1337
infections of, esophagogastroduodenoscopy in, 1197
laparoscopic surgery on, 1414–1415
motility disorders of, in irritable bowel syndrome, 1528–1529
polyps in, esophagogastroduodenoscopy in, 1177
ulcers of, endoscopic diagnosis and therapy of, 1337
vascular ectasia of, endoscopic diagnosis and therapy of, 1334–1336

Smoking, cessation of, massage therapy for, 166

SNAD4 gene, mutations of, in juvenile polyposis syndrome, 1487

Solitary rectal ulcer, sigmoidoscopy in, 1254–1255

Somatic pain, 775

Somatostatin, for varices, 1338

Somatotropin, for inflammatory bowel disease, 1512

Sorbitol, in end-of-life care, 761

Spider bites, versus erythema migrans, 251–252

Spiritual healing, 110–111. *See also* Prayer, in health care.

Spirituality, in end-of-life care, 766

Spirometry, postoperative, 743

Spongiform encephalopathy, transmissible. *See* Prion diseases.

Stagnation, blood, in Chinese medicine, 67

Standards of care, for complementary medicine, 193

STAT6 transcription factor, inhibitors of, for asthma, 1141–1142

Stavudine, for AIDS dementia, 545

Stent placement, in mesenteric ischemia, 1390

Stercoral ulcer, colonic, colonoscopy in, 1266

Still, Andrew Taylor, as osteopathy founder, 98

STK11-KLB1 gene, mutations of, in Peutz-Jeghers syndrome, 1486

Stomach
adenoma of, esophagogastroduodenoscopy in, 1198–1199
angiodysplasia of, esophagogastroduodenoscopy in, 1190–1191
bezoars in, esophagogastroduodenoscopy in, 1187–1188
cancer of, esophagogastroduodenoscopy in, 1200–1201
Dieulafoy's lesion of, bleeding in
angiography for, 1361
endoscopy in, 1332–1333
endoscopic ultrasonography of
in cancer, 1296–1297
in MALT lymphoma, 1297–1298
in submucosal masses, 1293–1294
in thickened wall, 1293
in varices, 1293
endoscopy of. *See* Esophagogastroduodenoscopy.
inflammation of. *See* Gastritis.
laparoscopic surgery on, 1412–1414
metaplasia of, in peptic ulcer disease, 1449–1450
peptic ulcer disease of. *See* Peptic ulcer disease.
polyps of
esophagogastroduodenoscopy in, 1198–1199
in familial adenomatous polyposis, 1482
stress injury of, esophagogastroduodenoscopy in, 1190
thickened folds in, esophagogastroduodenoscopy in, 1199–1200
tumors of, esophagogastroduodenoscopy in, 1199
varices of, endoscopic diagnosis and therapy of, 1188–1189, 1344
vascular ectasia of, esophagogastroduodenoscopy in, 1191–1192

Stool, composition of, in irritable bowel syndrome, 1535

Streptococcus pneumoniae bacteremia, treatment of, 803–805

Streptomycin, for tularemia, 402–403

Stress
- flower essence therapy for, 116–117
- gastric injury in,
  - esophagogastroduodenoscopy in, 1190
- irritable bowel syndrome and, 1532
- meditation in, 118–119
- peptic ulcer disease in, 1454–1455

Stress testing, for preoperative cardiac risk assessment, 799–800

Stretta endoscopic treatment, for Barrett's esophagus, 1430

Stroke
- rehabilitation in, biofeedback in, 24
- vascular dementia after. *See* Vascular dementia.

Subcortical dementia, 483–484

Subdural hematoma, chronic, versus dementia, 469

Substance abuse, meditation for, 14, 118–119

Sudation, in Ayurvedic medicine, 81

Suggestion, in energy medicine, 108

Sulfasalazine, for inflammatory bowel disease, 1500–1501

Sulindac, for familial adenomatous polyposis, 1484

Superficial syndrome, in Chinese medicine, 69

Superoxide dismutase, metal components of, prion diseases and, 566–567

Supplementation, in Chinese medicine, 67

Surgery
- for hospitalized patient. *See* Perioperative management.
- guided imagery in, 22–23
- hypnosis in, 20–21
- laparoscopic. *See* Laparoscopic surgery.

Swedish massage, 164

Swedish Movement System, 97

Swedish mutations, in Alzheimer's disease, 631, 634

Symptoms, consideration of, in homeopathy, 53–55

Synovial fluid analysis, in Lyme arthritis, 303–304

Syphilis, dementia in, 470

T

T lymphocytes, in asthma, 929, 1114–1116, 1132
- immunotherapy effects on, 1098
- in allergic response, 1093
- therapy based on, 1135–1140

Tacrine
- for Alzheimer's disease, 658–659
- for dementia with Lewy bodies, 527

Tapotement, 97

Target lesion. *See* Erythema migrans.

Tastes, in Ayurvedic medicine, 82

tau gene and protein, defects of
- diseases associated with, 501–502, 618–620
- in Alzheimer's disease, **615–627**
  - pathology of, 618–620
  - versus normal Tau protein, 615–618
- in frontotemporal dementia, 511–512, 603–604

Terbutaline, for asthma, 998, 1000–1001

Terminal care. *See* End-of-life care.

Tetracycline(s)
- for ehrlichiosis, 385
- for Lyme disease
  - chronic, 345–347
  - in carditis, 292
  - in erythema migrans, 256
- for Q fever, 412
- for relapsing fever, 429
- for Rocky Mountain spotted fever, 355
- for tularemia, 402–403

TGF-β RII gene, mutations of, in colorectal cancer, 1471

Thalidomide, for inflammatory bowel disease, 1509–1510

Theophylline, for asthma, 1062–1063, 1140

Therapeutic touch, 110–111

Thrombocytopenia, in ehrlichiosis, 382

Thrombolytic therapy, for mesenteric ischemia, occlusive, 1383

Thrombosis and thromboembolism, venous
diagnosis of, 807–812
mesenteric ischemia in, 1383–1384
postoperative, 743–744

Tiagabine, for pain, 789

Tick(s). *See also specific names.*
bites of
erythema migrans in. *See* Erythema migrans.
host reactions to, 211
management of, 226–228, 271
mechanisms of, 210
outcome of, 241
pathophysiology of, 210–211
risk factors for, 225–226
control of, 223–226, 369–370, 430
diseases borne by. *See also specific diseases, e.g.,* Babesiosis; Ehrlichiosis; Lyme disease.
prevention of, **219–238,** 430
bite management in, 226–228
bite prevention in, 223–226
Lyme vaccine in. *See* Vaccine, for Lyme disease.
tick biology and, 219–223
Q fever, 404–413
relapsing fever, **417–433**
tularemia, 393–403
hard-bodied. *See* Ixodidae; *specific tick genera.*
natural history of, **205–218**
attachment sites, 223
classification, 206–207
disease transmission capacity, 220
feeding, 209–211, 220–223, 421–422
habitats, 220–221
host interactions, 221
life cycles, 212–215, 364–365, 420–421
morphology, 207–209, 421–423
Ornithodoros, 420–422
overview, 205–206
pathogens and, 219–220
species, 206–207
water balance, 209
nymph form of
characteristics of, 222
feeding of, 211–215, 222
host interactions of, 221
morphology of, 207–208
removal of, 226–227, 445
repellents for, 226
soft-bodied. *See* Argasidae; *specific tick genera.*
toxins produced by, tick paralysis in, 441–446

Tick fever, Colorado. *See* Colorado tick fever.

Tick paralysis, **441–446**
clinical features of, 442–443
differential diagnosis of, 443–445
ticks involved in, 441–442
toxins in, 441–443
treatment of, 445
vectors for, 441–442

TNM staging, for cancer, endoscopic ultrasonography in, 1292

Tocopherol, supplementary, 131

Tolerance
of beta-agonists, 994–995
of opioids, 790–791

Tonification, in Chinese medicine, 67

Topiramate, for pain, 789

Touch, therapeutic, 110–111. *See also* Massage therapy.

Toupet fundoplication, laparoscopic, 1411

Toxins, dementia related to, 470

Trace elements, supplementary, 132–133

Traditional Chinese medicine. *See* Chinese medicine, traditional.

Trager method, for massage therapy, 164

Tramadol, for pain, 788

Trancelike state, in hypnosis, 18–21

Tranquilizers, for irritable bowel syndrome, 1542

Transcendental meditation, 13–15

Transcription factors, inhibitors of, for asthma, 1141–1142

Transcutaneous electrical nerve stimulation, for pain, 792

Transfusions, exchange, for babesiosis, 369

Transitional care, of elderly persons, 724–725

Transmissible spongiform encephalopathy. *See* Prion diseases.

Trazodone, for frontotemporal dementia, 512

Tremor, in dementia with Lewy bodies, 524–525

Triamcinolone, inhaled, for asthma. *See* Corticosteroids, for asthma, inhaled.

Tricylic antidepressants, for irritable bowel syndrome, 1540

Trisomy 21 (Down's syndrome), Alzheimer's disease-like pathology in, 633

Tularemia, 393–403
- animal models for, 398
- clinical manifestations of, 398–401
- diagnosis of, 401–402
- epidemiology of, 395–396
- glandular, 399
- historical origins of, 394–395
- host response in, 397–398
- laboratory testing for, 401–402
- microbiology of, 396–397
- mortality in, 403
- oculoglandular, 399
- oropharyngeal, 399–400
- pathogenesis of, 397–398
- pneumonic, 400–401
- prevention of, 403
- treatment of, 402–403
- typhoidal, 400
- ulceroglandular, 399
- vectors for, 395–396

Tumor(s)
- colonic. *See also* Colorectal cancer, colonoscopy in, 1263–1265
- gastric, esophagogastroduodenoscopy in, 1199

Tumor necrosis factor, inhibitors of, for inflammatory bowel disease, 1505–1510

Turcot's syndrome, 1485

Typhoidal tularemia, 400

U

Ubiquinone (coenzyme Q_{10}), as dietary supplement, 137–138

Ulcer(s)
- peptic. *See* Peptic ulcer disease.
- pressure, in elderly persons, in hospital, 721–722
- small intestinal, endoscopic diagnosis and therapy of, 1337
- solitary rectal, sigmoidoscopy in, 1254–1255
- stercoral, colonoscopy in, 1266

Ulcerative colitis
- adhesion molecule inhibitors for, 1511
- aminosalicylates for, 1500
- antibiotics for, 1503
- colonoscopy in, 1256
- corticosteroids for, 1502
- cytokine mediators for, 1510
- diagnosis of, 1500–1501
- endoscopic ultrasonography in, 1303
- genetics of, 1497–1498
- immunomodulators for, 1504–1505
- tumor necrosis factor inhibitors for, 1507–1508

Ulceroglandular tularemia, 399

Ultrasonography
- endoscopic, **1289–1317**
  - advantages of, 1289
  - anatomic considerations in, 1291–1292
  - esophageal, 1294–1296
  - for cancer staging, 1292
  - future uses of, 1308–1309
  - gastric, 1293–1294, 1296–1298
  - in choledocholithiasis, 1299
  - in non-small cell lung cancer, 1301–1302
  - instruments for, 1289–1290
  - interventional, 1304–1308
  - lower gastrointestinal, 1303–1304
  - pancreatic, 1298–1301
  - physics of, 1291
  - technique for, 1289–1292
  - training for, 1291
  - upper gastrointestinal, 1293–1302
- in mesenteric ischemia, 1387

Urea breath test, for *Helicobacter pylori*, 1455–1457

Urine test, for *Helicobacter pylori*, 1457

Urticaria, versus erythema migrans, 253–254

Utilization behavior, in frontotemporal dementia, 505

Utilization management, ethical issues in, 882–883

V

Vaccine(s)
- for asthma. *See also* Immunotherapy, for asthma.
  - DNA, 1145
- for ehrlichiosis, 386
- for Lyme disease, 229–233, 272
  - cost-effectiveness of, 231–232
  - disease diagnosis after, 232–233
  - efficacy of, 230–231
  - history of, 229

Vaccine(s) (*continued*)
laboratory testing after administration, 332–333
limitations of, 232
mechanism of action of, 229
safety of, 230–231

Valerian, 134
drug interactions with, 158
efficacy of, 151, 153
perioperative care and, 802

Variant Creutzfeldt-Jakob disease. *See* Creutzfeldt-Jakob disease, variant.

Varices
anorectal, sigmoidoscopy in, 1254
colonic
colonoscopy in, 1262
interventional radiology in, 1367–1374
esophageal. *See* Esophagus, varices of.
gastric, endoscopic diagnosis and therapy of, 1188–1189, 1293, 1344

Vascular dementia, **477–499**
acute-onset, 482
causes of, 477
clinical features of, 482–486, 598
definition of, 477
diagnosis of, 466, 486–489
differential diagnosis of, 578
epidemiology of, 480–481
genetics of, 598–599
historical background of, 477–478
in CADASIL, 485
in capsular genu infarction, 483–484
in cerebral amyloid angiopathy, 486
in lacunar stroke, 484
in single cortical-subcortical infarction, 483
pathogenesis of, 478–480
poststroke, 481–482
prevention of, 489–490
risk factors for, 482
senile, of Binswanger type, 484–485
subacute, 484
treatment of, 489–492, 667
versus Alzheimer's disease, 488–489

Vascular ectasia
gastric, esophagogastroduodenoscopy in, 1191–1192
gastrointestinal, endoscopic diagnosis and therapy of, 1334–1336

Vascular endothelial growth factor, in asthma, 930–931

Vasopressin, for gastrointestinal bleeding, 1362–1364, 1373

Vata, in Ayurvedic medicine, 77

Venous thrombosis and thromboembolism
diagnosis of, 807–812
mesenteric ischemia in, 1383–1384
postoperative, 743–744

Ventilation
mechanical. *See* Mechanical ventilation.
of environment, for fungal reduction, 985–986

Ventilation-perfusion ratio, beta-agonist effects on, 994

Verbal rating scales, for pain assessment, 777

Vertigo, homeopathy for, 57

Very late activation antigen-4, inhibitors of, for asthma, 1142

Vibration, in massage therapy, 97

Video technology
in colonoscopy, 1218, 1238, 1277–1279
in esophagogastroduodenoscopy, 1167

Viral infections, refractory asthma in, 1084

Virtual colonoscopy, 1278, 1472–1473

Visceral pain, 775

Visceral sensory disorders, in irritable bowel syndrome, 1529–1530

Visual analogue scale, for pain assessment, 777

Vitalistic theory, in homeopathy, 48–49

Vitamin(s)
for familial adenomatous polyposis, 1483–1484
supplementary, 130–131

Vitamin B_{12} deficiency, dementia in, 470–471

Vitamin E, for Alzheimer's disease, 664–665

Vocal cord dysfunction
in inhaled corticosteroid therapy, 1043
in refractory asthma, 1077–1078

Volvulus, colonoscopy in, 1269

Vomiting. *See* Nausea and vomiting.

W

Wandering, in dementia, treatment of, 646–647

Warfarin, for venous thromboembolism, postoperative, 744–745

Water, body, balance/imbalance of, in Chinese medicine, 67–68

Webs, esophageal, esophagogastroduodenoscopy in, 1195

Wernicke's encephalopathy, 470

Western blot test, for Lyme disease, 267, 328–330, 344–345

Western red cedar dust, asthma induced by, 954

Whipple's disease, esophagogastroduodenoscopy in, 1197

Whistleblowing, for errors, 885

Wholistic care. *See* Holistic care.

Wireless capsule enteroscopy, in bleeding, 1346–1347

Withholding and withdrawing life sustaining measures, in end-of-life care, 758

Wood tick, *See Dermacentor andersonii.*

World Health Organization, analgesic ladder of, 789–790

Y

Yang, in Chinese medicine, 66, 69

Yin, in Chinese medicine, 66, 69

Yoga, 78

Z

Zafirlukast, for asthma
- acute, 1061
- adverse effects of, 1028
- airway remodeling and, 1013
- antihistamines with, 1024
- availability of, 1010
- bronchodilating effects of, 1015
- exercise-induced, 1025
- mild, 1019–1020
- refractory, 1086–1087
- severe, 1023, 1061
- versus inhaled corticosteroids, 1040

Zalcitabine, for AIDS dementia, 545

Zidovudine, for AIDS dementia, 545–546

Zileuton, for asthma
- adverse effects of, 1028
- anti-inflammatory effects of, 1013
- aspirin-sensitive, 1027
- availability of, 1010
- mild, 1020

Zollinger-Ellison syndrome, gastrinoma in, 1194